WO2023186881A1 - P38 map kinase inhibitors for use in the treatment of colorectal cancer - Google Patents
P38 map kinase inhibitors for use in the treatment of colorectal cancer Download PDFInfo
- Publication number
- WO2023186881A1 WO2023186881A1 PCT/EP2023/057981 EP2023057981W WO2023186881A1 WO 2023186881 A1 WO2023186881 A1 WO 2023186881A1 EP 2023057981 W EP2023057981 W EP 2023057981W WO 2023186881 A1 WO2023186881 A1 WO 2023186881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- solvate
- acceptable salt
- optical isomer
- Prior art date
Links
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 39
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 38
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title claims abstract description 9
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title abstract description 19
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 83
- 238000006243 chemical reaction Methods 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000012453 solvate Substances 0.000 claims description 24
- 230000003287 optical effect Effects 0.000 claims description 23
- 229910052736 halogen Chemical group 0.000 claims description 14
- 150000002367 halogens Chemical group 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 238000002875 fluorescence polarization Methods 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 66
- -1 N-morpholinyl Chemical group 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000007787 solid Substances 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000002609 medium Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 210000002220 organoid Anatomy 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 241001529936 Murinae Species 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000007832 Na2SO4 Substances 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- SBUOAPYCHJMYIZ-UHFFFAOYSA-N 13-[3-(cyclopropanecarbonylamino)-4-fluoroanilino]-N-methyl-2-oxotricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene-5-carboxamide Chemical compound CNC(=O)c1ccc2CCc3cc(Nc4ccc(F)c(NC(=O)C5CC5)c4)ccc3C(=O)c2c1 SBUOAPYCHJMYIZ-UHFFFAOYSA-N 0.000 description 4
- IYOZTVGMEWJPKR-VOMCLLRMSA-N 4-[(1R)-1-aminoethyl]-N-pyridin-4-yl-1-cyclohexanecarboxamide Chemical compound C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-VOMCLLRMSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 239000012580 N-2 Supplement Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 102000045246 noggin Human genes 0.000 description 3
- 108700007229 noggin Proteins 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- BKWJAKQVGHWELA-UHFFFAOYSA-N 1-[6-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-[4-(4-methyl-1-piperazinyl)anilino]-2-prop-2-enyl-3-pyrazolo[3,4-d]pyrimidinone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N(CC=C)N(C=3N=C(C=CC=3)C(C)(C)O)C2=N1 BKWJAKQVGHWELA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- KJVBJICWGQIMOZ-UHFFFAOYSA-N 2-fluoro-5-nitroaniline Chemical compound NC1=CC([N+]([O-])=O)=CC=C1F KJVBJICWGQIMOZ-UHFFFAOYSA-N 0.000 description 2
- JZCWLJDSIRUGIN-UHFFFAOYSA-N 3-[3-[4-(methylaminomethyl)phenyl]-5-isoxazolyl]-5-(4-propan-2-ylsulfonylphenyl)-2-pyrazinamine Chemical compound C1=CC(CNC)=CC=C1C1=NOC(C=2C(=NC=C(N=2)C=2C=CC(=CC=2)S(=O)(=O)C(C)C)N)=C1 JZCWLJDSIRUGIN-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- DOTGPNHGTYJDEP-UHFFFAOYSA-N 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1h-pyrazol-3-yl]amino]pyrazine-2-carbonitrile Chemical compound COC1=CC=CC(OCCCN)=C1C1=CC(NC=2N=CC(=NC=2)C#N)=NN1 DOTGPNHGTYJDEP-UHFFFAOYSA-N 0.000 description 2
- IFPPYSWJNWHOLQ-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2Cl)Cl)C(=O)N2C)C2=N1 IFPPYSWJNWHOLQ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 102100036428 Spondin-1 Human genes 0.000 description 2
- 101710092167 Spondin-1 Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000005042 acyloxymethyl group Chemical group 0.000 description 2
- 229950009557 adavosertib Drugs 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229950009676 berzosertib Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229960005419 nitrogen Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229950010660 prexasertib Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229960004836 regorafenib Drugs 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DWYRIWUZIJHQKQ-SANMLTNESA-N (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine Chemical compound Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1 DWYRIWUZIJHQKQ-SANMLTNESA-N 0.000 description 1
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 1
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 1
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 1
- 125000005851 1-(N-(alkoxycarbonyl)amino)ethyl group Chemical group 0.000 description 1
- 125000005846 1-(alkanoyloxy)ethyl group Chemical group 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- BOVQCIDBZXNFEJ-UHFFFAOYSA-N 1-chloro-3-ethenylbenzene Chemical compound ClC1=CC=CC(C=C)=C1 BOVQCIDBZXNFEJ-UHFFFAOYSA-N 0.000 description 1
- 125000005847 1-methyl-1-(alkanoyloxy)-ethyl group Chemical group 0.000 description 1
- 125000005849 1-methyl-1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- CEVXTZKLIGTUFI-UHFFFAOYSA-N 2-(2,4-difluoro-5-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC([N+]([O-])=O)=C(F)C=C1F CEVXTZKLIGTUFI-UHFFFAOYSA-N 0.000 description 1
- WUKHOVCMWXMOOA-UHFFFAOYSA-N 2-(3-nitrophenyl)acetic acid Chemical class OC(=O)CC1=CC=CC([N+]([O-])=O)=C1 WUKHOVCMWXMOOA-UHFFFAOYSA-N 0.000 description 1
- XRKYMMUGXMWDAO-UHFFFAOYSA-N 2-(4-morpholinyl)-6-(1-thianthrenyl)-4-pyranone Chemical compound O1C(C=2C=3SC4=CC=CC=C4SC=3C=CC=2)=CC(=O)C=C1N1CCOCC1 XRKYMMUGXMWDAO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 1
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FQPQMJULRZINPV-UHFFFAOYSA-N 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one Chemical compound CC1=CN=C(C=2N=C(N=CC=2)C(C)(C)O)C=C1N(C(C=1Cl)=O)C(C)=CC=1OCC1=NC=C(F)C=C1F FQPQMJULRZINPV-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AFPHTEQTJZKQAQ-UHFFFAOYSA-N 3-nitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-N 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- JHNLZOVBAQWGQU-UHFFFAOYSA-N 380814_sial Chemical compound CS(O)(=O)=O.O=P(=O)OP(=O)=O JHNLZOVBAQWGQU-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- VQSZIPCGAGVRRP-UHFFFAOYSA-N 7-fluoro-3-methyl-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]quinolin-2-one Chemical compound FC=1C(=CC=2C3=C(C=NC=2C=1)N(C(N3C(C)C)=O)C)C=1C=NC(=CC=1)OCCCN1CCCCC1 VQSZIPCGAGVRRP-UHFFFAOYSA-N 0.000 description 1
- XISVSTPEXYIKJL-UHFFFAOYSA-N 7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(oxan-4-yl)purin-8-one Chemical compound CN1C(=O)N(C2CCOCC2)C2=NC(NC3=CN4N=CN=C4C=C3C)=NC=C12 XISVSTPEXYIKJL-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- AOTRIQLYUAFVSC-UHFFFAOYSA-N 8-[6-[3-(dimethylamino)propoxy]pyridin-3-yl]-3-methyl-1-(oxan-4-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN(CCCOC1=CC=C(C=N1)C1=CC=2C3=C(C=NC2C=C1)N(C(N3C3CCOCC3)=O)C)C AOTRIQLYUAFVSC-UHFFFAOYSA-N 0.000 description 1
- 102000003736 ATP Synthetase Complexes Human genes 0.000 description 1
- 108010082072 ATP Synthetase Complexes Proteins 0.000 description 1
- 229940127011 AZD1390 Drugs 0.000 description 1
- 229940126288 AZD7648 Drugs 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- YPKJHSWQZLJHLL-UHFFFAOYSA-N C1=CC2=C(C=C1C(=O)OC)C(=O)C1=CC=C(Cl)C=C1CC2 Chemical compound C1=CC2=C(C=C1C(=O)OC)C(=O)C1=CC=C(Cl)C=C1CC2 YPKJHSWQZLJHLL-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- YQQZZYYQTCPEAS-OYLFLEFRSA-N ClC=1C(=C(C=CC=1)CN1[C@@H](C[C@@](CC1)(C(=O)O)CC1=NC(=CC=C1F)NC1=NNC(=C1)C)C)F Chemical compound ClC=1C(=C(C=CC=1)CN1[C@@H](C[C@@](CC1)(C(=O)O)CC1=NC(=CC=C1F)NC1=NNC(=C1)C)C)F YQQZZYYQTCPEAS-OYLFLEFRSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-O Htris Chemical compound OCC([NH3+])(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-O 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 description 1
- 108010066370 Keratin-20 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- 108010064641 ONX 0912 Proteins 0.000 description 1
- 101150062285 PGF gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 108030005449 Polo kinases Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 229950009821 acalabrutinib Drugs 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000012574 advanced DMEM Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229950009447 alisertib Drugs 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 229950009576 avapritinib Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229950004272 brigatinib Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229950005852 capmatinib Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical compound C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002271 cobimetinib Drugs 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 229950001466 delanzomib Drugs 0.000 description 1
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- RMGPQSLGFYZHNF-UHFFFAOYSA-N dimethyl 4-[2-(3-chlorophenyl)ethyl]benzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC(C(=O)OC)=CC=C1CCC1=CC=CC(Cl)=C1 RMGPQSLGFYZHNF-UHFFFAOYSA-N 0.000 description 1
- ADXCABFZLVXCNW-UHFFFAOYSA-N dimethyl 4-bromobenzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC=C(Br)C(C(=O)OC)=C1 ADXCABFZLVXCNW-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229950001969 encorafenib Drugs 0.000 description 1
- 229950000521 entrectinib Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229950004444 erdafitinib Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003487 fedratinib Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 229950005309 fostamatinib Drugs 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 229950006304 gilteritinib Drugs 0.000 description 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- VBCVPMMZEGZULK-NRFANRHFSA-N indoxacarb Chemical compound C([C@@]1(OC2)C(=O)OC)C3=CC(Cl)=CC=C3C1=NN2C(=O)N(C(=O)OC)C1=CC=C(OC(F)(F)F)C=C1 VBCVPMMZEGZULK-NRFANRHFSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001793 isothiazol-3-yl group Chemical group [H]C1=C([H])C(*)=NS1 0.000 description 1
- 125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 description 1
- 125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 1
- 229960003648 ixazomib Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229950003970 larotrectinib Drugs 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229950001290 lorlatinib Drugs 0.000 description 1
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- LLYKPZOWCPVRPD-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine;n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=CC=N1 LLYKPZOWCPVRPD-UHFFFAOYSA-N 0.000 description 1
- WPHOKOCRXFVQBA-UHFFFAOYSA-N n-(2-fluoro-5-nitrophenyl)cyclopropanecarboxamide Chemical compound [O-][N+](=O)C1=CC=C(F)C(NC(=O)C2CC2)=C1 WPHOKOCRXFVQBA-UHFFFAOYSA-N 0.000 description 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 1
- 229950008089 omipalisib Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000006712 oncogenic signaling pathway Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229950005750 oprozomib Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940121317 pemigatinib Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 1
- 229950001457 pexidartinib Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000005856 piperidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940121597 pralsetinib Drugs 0.000 description 1
- GBLBJPZSROAGMF-BATDWUPUSA-N pralsetinib Chemical compound CO[C@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 GBLBJPZSROAGMF-BATDWUPUSA-N 0.000 description 1
- 238000000039 preparative column chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000005857 pyrrolidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 description 1
- 229950002836 retaspimycin Drugs 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 229940121487 ripretinib Drugs 0.000 description 1
- CEFJVGZHQAGLHS-UHFFFAOYSA-N ripretinib Chemical compound O=C1N(CC)C2=CC(NC)=NC=C2C=C1C(C(=CC=1F)Br)=CC=1NC(=O)NC1=CC=CC=C1 CEFJVGZHQAGLHS-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940121610 selpercatinib Drugs 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004297 tetrahydropyrrol-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229950003463 tucatinib Drugs 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 229950000088 upadacitinib Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 1
- 229960001183 venetoclax Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229950007153 zanubrutinib Drugs 0.000 description 1
- 229940125362 zunsemetinib Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
- C07D333/44—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms attached in position 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Definitions
- the invention relates to p38 MAP kinase inhibitors of formula (I) as shown below for use in the treatment of colorectal cancer.
- MAP mitogene activated protein
- TRT drug-target residence time
- p38a MAP kinase inhibitors have resulted in a longer target residence time (TRT) by developing the novel type l 1 Z> binding mode, J. Med. Chem. 2017, 60, 19, 8027- 8054 and doctoral thesis Heike Wentsch, Eberhard Karls Universitat Tubingen 2017 as well as doctoral thesis Niklas Walter, Eberhard Karls Universitat Tubingen 2017. Inspite of all efforts, no p38a MAP kinase inhibitor has yet been launched into the market. Even drugs with a very high TRT failed, such as BIRB 796 (doramapimod).
- Colorectal cancer is currently the 3rd most commonly diagnosed malignancy and the 2nd leading cause of cancer related death worldwide. In 2020, more than 1.8 million new cases and more than 900,000 deaths were reported. Surgical resection or endoscopic excision of localized tumors and polyps represents an efficient therapeutic option for patients. However, around one quarter of colorectal cancers are diagnosed at an advanced stage with a metastatic disease and ⁇ 20% of cases develop metachronous metastases upon surgical removal of the primary tumor, Lancet 2019;394(10207):1467-80 doi 10.1016/S0140- 6736(19)32319-0.
- Stage IV colorectal cancer patients that were treated with a combination of Oxaliplatin- and Irinotecan based chemotherapies and monoclonal antibodies directed against VEGFR or EGFR only show a median survival between 2 and 2.5 years, Signal Transduct Target Ther 2020;5(1):22 doi 10.1038/s41392-020-0116-z.
- Checkpoint blocking antibodies like anti-PD1 or anti-CTLA4 show only a limited activity against colorectal cancer.
- the problem underlying the invention was therefore to provide compounds which are effective in the treatment of colorectal cancer.
- R 1 is -CONR 6 R 7 ;
- R 2 is alkyl or halogen
- R 3 is H or halogen;
- R 4 is -L 2 -R 5 ;
- L 2 is i— NR 6 -CO- -NR 6 -CO-NR 6 -, or i-CH 2 CO-;
- R 5 is selected from phenyl, optionally substituted with 1 or 2 substituents independently selected from halogen, alkoxy and haloalkyl, an aromatic 5- or 6-membered heterocyclic group having 1 or 2 heteroatoms independently selected from N, S and O, and cycloalkyl;
- R 6 is H or alkyl
- R 7 is selected from H, alkyl, alkyl which is substituted with a non-aromatic 5- or 6- membered heterocyclic group having 1 or 2 heteroatoms independently selected from N and O, alkyl substituted with 1 or 2 hydroxy groups and alkyl substituted with hydroxyalkyl-NR 6 -; wherein here and in any following occasion ⁇ in the meanings of L 2 indicates the attachment to ring C.
- the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or optical isomer thereof for use in treating colorectal cancer, wherein the compound has a Target Residence Time (TRT) of at least 500 s, preferably at least 900 s, and in particular at least 1000 s, as determined by a fluorescence polarization assay by directly measuring the ADP formed by p38 MAPK kinase reaction.
- TRT Target Residence Time
- R 2 and R 3 are halogen or both of them are halogen.
- R 2 is halogen and R 3 is H or halogen.
- the halogen in these embodiments is preferably F or Cl, in particular F.
- L 2 is ⁇ — NR 6 -CO- or -NR 6 -CO-NR 6 -, in particular ⁇ — NR 6 -CO-.
- R 5 is an aromatic 5- or 6-membered heterocyclic group, it is preferably pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrimidyl, in particular thienyl or furyl, and more particularly thienyl.
- R 5 is selected from phenyl, thienyl or cycloalkyl, in particular cycloalkyl. Cycloalkyl is preferably cyclopropyl.
- L 2 is ⁇ — NR 6 -CO- or -NR 6 -CO-NR 6 - and R 5 is selected from thienyl or cycloalkyl, preferably cyclopropyl.
- L 2 is ⁇ — CH2CO and R 5 is phenyl.
- R 6 is H and R 7 is H.
- R 6 is H and R 7 is alkyl, in particular Ci-Cs-alkyl or alkyl, preferably C2-C4 alkyl, substituted with a saturated non-aromatic 5- or 6-membered heterocyclic group having 2 heteroatoms independently selected from N and O.
- the non-aromatic 5- or 6- membered heterocyclic group is preferably N-morpholinyl or N-piperazinyl, in particular morpholino-N-C2-C4 alkyl, such as morpholino-N-ethyl.
- R 6 is H and R 7 is alkyl, in particular Ci-Cs-alkyl.
- R 6 is H and R 7 is alkyl substituted with 1 or 2 hydroxy groups, such as 2-hydroxyethyl or 2,3-dihydroxypropyl.
- R 6 is H and R 7 is C2-C4 alkyl which is substituted with with a hydroxy-C2-Cs alkylamino group.
- the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use in treating colorectal cancer, wherein the compound is selected from the compounds of table 1 :
- the invention relates to a compound of formula (la) having the formula or a pharmaceutically acceptable salt, solvate or optical isomer thereof.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising the compound of formula (la) or a pharmaceutically acceptable salt, solvate or optical isomer thereof, as well as to said compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use in treating cancer, in particular colorectal cancer.
- the pharmaceutically acceptable salts of the compounds of the invention are especially acid or base addition salts with pharmaceutically acceptable acids or bases.
- suitable pharmaceutically acceptable organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, sulfamic acid, Ci-C4-alkylsulfonic acids, such as methanesulfonic acid, cycloaliphatic sulfonic acids, such as S-(+)-10-camphor sulfonic acid, aromatic sulfonic acids, such as benzenesulfonic acid and toluenesulfonic acid, di- and tricarboxylic acids and hydroxycarboxylic acids having 2 to 10 carbon atoms, such as oxalic acid, malonic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, glycolic acid, adipic acid and benzoic acid.
- organic and inorganic bases are alkali metal hydroxides, such as sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides such as calcium or magnesium hydroxide, ammonium hydroxide, organic nitrogen bases such as dimethylamine, trimethylamine, ethanolamine, diethanolamine, triethanolamine, choline, 2-amino-2-hydroxymethyl-propane- 1 ,3-diol, meglumine, procaine etc.
- the invention also includes any tautomeric, crystal and polymorphic form of said compounds and salts and mixtures thereof.
- the invention also includes solvates such as hydrates.
- the compounds contemplated may contain one or more chiral centers, and exist in different optically active forms such enantiomers and diastereomers.
- the invention also refers to the pro-drugs of the compounds of the invention.
- prodrug refers to an agent which is converted into the parent drug in vivo by some physiological chemical process.
- An example, without limitation, of a pro-drug would be a compound of the present invention in the form of an ester.
- Pro-drugs have many useful properties. For example, a pro-drug may be more water soluble than the ultimate drug, thereby facilitating intravenous administration of the drug. A pro-drug may also have a higher level of oral bioavailability than the ultimate drug. After administration, the prodrug is enzymatically or chemically cleaved to deliver the ultimate drug in the blood or tissue.
- pro-drugs include, but are not limited to, compounds with carboxylic acid substituents wherein the free hydrogen is replaced by (Ci-C4)alkyl, (Ci- Ci2)alkanoyloxy-methyl, (C4-Cg)1-(alkanoyloxy)ethyl, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1- (alkoxycarbonyl-oxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)- ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3- phthalidyl, 4-crotono-lactonyl, gamma
- exemplary pro-drugs release an alcohol of Formula (I) wherein the free hydrogen of the hydroxyl substituent (e.g., R group contains hydroxyl) is replaced by (Ci-C6)alkanoyloxy-methyl, 1-((Ci-Ce)alkanoyloxy)- ethyl, 1-methyl-1-((Ci-C6)alkanoyloxy)ethyl, (Ci-Ci2)alkoxy-carbonyloxy-methyl, N-(Ci-Ce)- alkoxy-carbonylaminomethyl, succinoyl, (Ci-Ce)alkanoyl, a-amino(Ci-C4)alkanoyl, arylactyl and a-aminoacyl, or a-aminoacyl-a-aminoacyl wherein said a-aminoacyl moieties are independently any of the naturally occurring L-amino acids found in proteins, P(O)(OH)2, - P(
- halogen denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine or chlorine, and most preferably fluorine.
- Alkyl is a straight-chain or branched alkyl group which is preferably a Ci-Ce-alkyl group, i.e. an alkyl group having from 1 to 6 carbon atoms, and more preferably a Ci-C4-alkyl group.
- Examples of an alkyl group are methyl, ethyl, n-propyl, iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl.
- alkyl is likewise applicable to any group which includes an alkyl group.
- Cycloalkyl is a cycloaliphatic radical which is preferably Cs-Cs-cycloalkyl, i.e. a cycloalkyl group having from 3 to 8 carbon atoms and, in particular, 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- An aromatic heterocyclic group is a 5- or 6-membered monocyclic aromatic group having 1 or 2 heteroatoms independently selected from O, N and S.
- the aromatic heterocyclic group may be bound to the neighboring group via a carbon atom (C-bound) or via a nitrogen heteroatom (N-bound). Examples are:
- C-bound, 6-membered, heteroaromatic rings pyridin-2-yl, pyridin-3-yl (3-pyridyl), pyridin-4-yl (4-pyridyl), pyridin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyridazin-6-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-5-yl;
- N-bound, 5-membered, heteroaromatic rings pyrrol-1-yl, pyrazol-1-yl, imidazol-1-yl.
- a non-aromatic 5- or 6-membered heterocyclic group is a saturated group and includes in general 1 or 2 heteroatoms selected from O, N and S.
- the heterocyclic radicals may be bound via a carbon atom (C-bound) or a nitrogen atom (N-bound).
- Preferred heterocyclic groups comprise 1 nitrogen atom as ring member atom and optionally 1 further heteroatom as ring members, which are selected, independently of each other from O, S and N. Examples are:
- C-bound, 4-membered rings such as azetidin-2-yl, azetidin-3-yl, oxetan-2-yl, oxetan-3-yl
- C-bound, 5-membered rings such as tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetrahydropyrrol-2-yl, tetrahydropyrrol-3-yl, tetrahydropyrazol-3-yl, tetrahydro-pyrazol-4-yl;
- C-bound, 6-membered rings such as tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 1,3-dioxan-2-yl, 1,3-dioxan- 4-yl, 1,3-dioxan-5-yl, 1,4-dioxan-2-yl;
- N-bound, 4-membered rings such as azetidin-1-yl
- N-bound, 5-membered rings such as tetrahydropyrrol- 1-yl (pyrrolidin-1 -yl), tetrahydropyrazol-1-yl;
- N-bound, 6-membered rings such as morpholin-1-yl, piperazin-1 -yl, piperidin-1-yl, hexahydropyrimidin-1-yl, hexahydropyrazin-1-yl (piperazin-1 -yl), hexahydro-pyridazin-1-yl;
- Any group containing heteroatoms may contain 1 , 2 or 3 heteroatoms which may be the same or different.
- compositions which comprise at least one compound of the invention, optionally together with an inert carrier (e.g. a pharmaceutically acceptable excipient) and, where appropriate, other drugs.
- inert carrier e.g. a pharmaceutically acceptable excipient
- other drugs e.g. a pharmaceutically acceptable excipient
- compositions can, for example, be administered orally, rectally, transdermally, subcutaneously, intraperitoneally, intravenously, intramuscularly or intranasally.
- suitable pharmaceutical compositions are solid medicinal forms, such as powders, granules, tablets, in particular film tablets, lozenges, sachets, cachets, sugar- coated tablets, capsules, such as hard gelatin capsules and soft gelatin capsules, or suppositories, semisolid medicinal forms, such as ointments, creams, hydrogels, pastes or plasters, and also liquid medicinal forms, such as solutions, emulsions, in particular oil-in- water emulsions, suspensions, for example lotions, injection preparations and infusion preparations.
- liposomes or microspheres are examples of suitable pharmaceutical compositions.
- the compounds of the invention are optionally mixed or diluted with one or more carriers (excipients).
- Carriers can be solid, semisolid or liquid materials which serve as vehicles, carriers or medium for the active compound. Suitable carriers (excipients) are listed in the specialist medicinal monographs.
- the formulations can comprise pharmaceutically acceptable auxiliary substances, such as wetting agents; emulsifying and suspending agents; preservatives; antioxidants; antiirritants; chelating agents; coating auxiliaries; emulsion stabilizers; film formers; gel formers; odor masking agents; taste corrigents; resins; hydrocolloids; solvents; solubilizers; neutralizing agents; diffusion accelerators; pigments; quaternary ammonium compounds; refatting and overfatting agents; raw materials for ointments, creams or oils; silicone derivatives; spreading auxiliaries; stabilizers; sterilants; suppository bases; tablet auxiliaries, such as binders, fillers, glidants, disintegrants or coatings; propellants; drying agents; opacifiers; thickeners; waxes; plasticizers and white mineral oils.
- auxiliary substances such as wetting agents; emulsifying and suspending agents; preservatives; antioxidants; antiirritants; chel
- a formulation in this regard is based on specialist knowledge as described, for example, in Fiedler, H.P., Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende füre [Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields], 4 th edition, Aulendorf: ECV-Editio-Cantor-Verlag, 1996.
- the compounds of the invention may also be suitable for combination with other therapeutic agents and therapeutic approaches.
- the invention therefore further relates to a combination comprising a compound of the invention with one or more further therapeutic agents or therapeutic approaches.
- Suitable agents and approaches for use in combination with the compounds of the invention include for example:
- Antineoplastic agents and combinations thereof such as DNA alkylating agents (for example Cisplatin, Oxaliplatin, Carboplatin, Cyclophosphamide, nitrogen mustards like Ifosfamide, Bendamustine, Melphalan, Chlorambucil, Busulphan, Temozolamide and itrosoureas like Carmustine), antimetabolites (for example Gemcitabine and antifolates such as fluoropyrimidines like 5-Fluorouracil, Capecitabine and Tegafur, Raltitrexed, Methotrexate, Cytosine Arabinoside, and Hydroxyurea), anti-tumor antibiotics (for example anthracyclines like Bleomycin, Doxorubicin, Liposomal doxorubicin, Pirarubicin, Daunomycin, Valrubicin, Epirubicin, Idarubicin, Mitomycin-C, Dactinomycin, Amrubicin and Mithramycin), antimitotic agents (
- Agents that inhibit protein-protein interactions for example Venetoclax, Navitoclax
- proteasome for example Bortezomib, Carfilzomib, Ixazomib, Marizomib Delanzomib, Oprozomib
- Agents that inhibit protein phosphorylation such as Abemaciclib, Acalabrutinib, Adavosertib, Afatinib, Aflibercept, Alectinib, Alisertib, Avapritinib, Axitinib, Berzosertib, Binimetinib, Bosutinib, Brigatinib, Cabozantinib, Capmatinib, Cetuximab, Ceritinib, Cobimetinib, Crizotinib, Dabrafenib, Dacomitinib, Dasatinib, Encorafenib, Entrectinib, Erdafitinib, Erlotinib, Everolimus, Fedratinib, Fostamatinib, Gefitinib, Gilteritinib, Ibrutinib, Imatinib, Lapatinib, Larotrectinib, Lenvatinib, Lor
- Agents that block angiogenesis such as compounds that inhibit the effects of vascular endothelial growth factor, for example the anti-vascular endothelial cell growth factor antibody Bevacizumab and VEGF receptor tyrosine kinase inhibitors such as Vandetanib, Sorafenib, Regorafenib, Vatalanib, Sunitinib, Axitinib, Pazopanib and Cediranib, compounds such as those disclosed in W097/22596, WO 97/30035, WO 97/32856 and WO 98/13354, and compounds that work by other mechanisms (for example linomide, inhibitors of integrin czvB3 function and angiostatin), or inhibitors of angiopoietins and their receptors (Tie-I and Tie-2), inhibitors of PLGF, inhibitors of delta-like ligand (DLL-4).
- vascular endothelial growth factor for example the anti-vascular
- Immunotherapeutic approaches to increase the immunogenicity of patient tumor cells such as transfection with cytokines (for example interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor), approaches to decrease T-cell anergy or regulatory T-cell function, approaches that enhance T -cell responses to tumors, such as blocking antibodies to CTLA4 (for example ipilimumab and tremelimumab), B7HI, PD-I (for example BMS-936558 or AMP-514), PD-LI (for example MED14736) and agonist antibodies to CD137 and other immune checkpoint inhibitors, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumor cell lines, approaches using antibodies to tumor associated antigens, and antibodies that deplete target cell types (e.g.
- cytokines for example interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor
- unconjugated anti-CD20 antibodies such as Rituximab, radiolabeled anti-CD20 antibodies Bexxar and Zevalin and anti-CD54 antibody Campath), approaches using anti-idiotypic antibodies, approaches that enhance Natural Killer cell function, and approaches that utilize antibodytoxin conjugates (e.g.
- immunotoxins such as Moxetumumab Pasudotox, agonists of toll-like receptor 7 or toll-like receptor 9, cellular immunotherapies for example CAR-T cell therapy, NK cell therapy, CAR-NK cell therapy, tumor-infiltrating lymphocytes, recombinant T cells, vaccinations for example anti-tumor peptide vaccines, mRNA vaccines and dendritic cell vaccines.
- the combination therapies of the invention may be administered adjunctively.
- adjunctive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices.
- This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as addon therapeutic administration.
- Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of the invention and at least one further therapeutic agent are within the scope of the current invention.
- a patient is typically stabilized on a therapeutic administration of one or more of the components for a period of time and then receives administration of another component.
- the combination therapies of the invention may also be administered simultaneously.
- simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, administered simultaneously.
- Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.
- the invention also relates to the use of a compound of the invention for treating colorectal cancer. In another embodiment the invention also relates to the use of a compound of the invention for preparing apharmaceutical composition for treating colorectal cancer.
- the invention also relates to a method of treating colorectal cancer which comprises administering an effective amount of a compound of the invention or a composition as defined above to a subject in need thereof.
- the compounds of the invention are administered in a dosage of 5 to 50 mg/kg, in particular 10 to 30 mg/kg, for example 20 mg/kg, of the subject being treated.
- the compounds can be administered once or several times a day.
- the compounds are administered up to at least 10 weeks.
- Preparative column chromatography was carried out with an Interchim Puri Flash 430 or Puri Flash XS420 automated flash chromatography system and were unless otherwise stated performed on normal phase silica gel (Grace Davison Davisil LC60A 20-45 micron or Merck Geduran Si60 63-200 micron).
- MS Mass spectra were obtained using a Advion TLC-MS interface with electron spray ionization (ESI) in positive and/or negative mode. Instrument settings as follows: ESI voltage 3,50 kV, capillary voltage 187 V, source voltage 44 V, capillary temperature 250 °C, desolvation gas temperature 250 °C, gas flow 5 l/min nitrogen.
- HPLC High Performance Liquid Chromatography: Purity of final compounds was determined using an Agilent 1100 Series LC with Phenomenex Luna C8 columns (150 x 4.6 mm, 5 pm) and detection was performed with a UV DAD at 254 nm and 230 nm wavelength. Elution was carried out with the following gradient: 0.01 M KH2PO4, pH 2.30 (solvent A), MeOH (solvent B), 40 % B to 85 % B in 8 min, 85 % B for 5 min, 85 % to 40 % B in 1 min, 40 % B for 2 min, stop time 16 min, flow 1 .5 ml/min. All final compounds showed a purity above 95% in the means of area percent at the two different wavelengths.
- the compounds of the invention can be prepared by the synthetic procedures described in J Med Chem 2013, 56(1), 241-253, J. Med. Chem. 2017, 60, 19, 8027-8054, doctoral thesis Heike Wentsch, Eberhard Karls Universitat Tubingen 2017 and doctoral thesis Niklas Walter, Eberhard Karls Universitat Tubingen 2017 or analogous procedures.
- As examplary procedures given in these publications the synthesis of compounds 1 and 4 (see table 1) is described in detail as follows:
- Step 1 Dimethyl (E)-4-(3-chlorostyryl)isophthalate (S1).
- Tetrabutylammoniumchloride (336 mg, 1.21 mmol, 0.1 eq) by heating under vacuum. Under argon atmosphere were added dimethyl 4- bromoisophthalate (3.31 g, 12.1 mmol, 1.0 eq), /V,/V-dicyclohexyl methylamine (3.54 g, 18.15 mmol, 1.5 eq), 3-chloro styrene (1.84 g, 13.31 mmol, 1.1 eq) and 20 mL dry dioxane.
- Step 2 Dimethyl 4-(3-chlorophenethyl)isophthalate (S2).
- the catalyst was removed by filtration over a bed of celite and was thoroughly washed with EtOAc. To remove the aliphatic inpurities of the previous step the filtrate was washed successively with 2 M KHSO4 (3x30 mL), water (30 mL), sat. NaHCOs (30 mL) and brine (30 ml). The organic phase was dried over Na2SO4, concentrated under reduced pressure and coevaporated several times with MeOH and DCM to remove traces of water. Yield: 3.07 g (87 %) as a clear viscous oil which crystallizes upon standing.
- Step 3 Methyl 8-chloro-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxylate (S3).
- Step 4 8-Chloro-N-methyl-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamide (S4).
- Step 5.2 N-(5-Amino-2-fluorophenyl)cyclopropanecarboxamide (S5.2).
- Step 6 8-((3-(Cyclopropanecarboxamido)-4-fluorophenyl)amino)-N-methyl-5-oxo-10,11- dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamide (1)
- Step 1.1 1-Cyclopropyl-3-(2-fluoro-5-nitrophenyl)urea (4.1).
- Step 1.2 1-(5-Amino-2-fluorophenyl)-3-cyclopropylurea (4.2).
- Step 3 8-((3-(3-Cyclopropylureido)-4-fluorophenyl)amino)-N-methyl-5-oxo-10,11-dihydro-5H- dibenzo[a,d][7]annulene-3-carboxamide 4.
- Ketone derivatives were accessible via one of the above depicted synthetic routes starting from the 3-nitro phenylacetic acid derivatives or 3-nitro benzoic acid derivatives using either an activation to the acid chloride and a subsequent Friedel-Crafts acylation or the transformation to the corresponding Weinreb amide and subsequent reaction with organometallic reagents.
- the aniline for Buchwald-Hartwig was then obtained by reduction of the nitro group using state of the art reductive methods like tin(ll)chloride in ethanol or elemental hydrogen in combination with palladium on charcoal.
- Murine colon organoids were isolated from genetically modified mice as described before (Sato et al., Nature 459, 262-265, 2009). The tissue fragments were washed with ice-cold PBS (phosphate buffered saline), transferred to 2 mM EDTA chelating buffer and incubated for 30 mins at 4°C on an orbital shaker. Subsequently, the supernatant was removed and the tissue fragments were resuspended in medium containing 10% FCS (Fetal Calf Serum, table 3).
- PBS phosphate buffered saline
- FCS Fetal Calf Serum
- the supernatant containing crypts were centrifuged at 150 g for 5 mins and colonic crypts were embedded in 50 pl domes of Growth Factor Reduced (GFR) MatrigelTM (Corning) in 24-well plates. Following polymerization for 10 mins at 37°C, MatrigelTM (Corning) domes were overlaid with murine colon medium (table 3), supplemented with 10.5 pM Y-27632 dihydrochloride (Invitrogen) for the three days.
- GFR Growth Factor Reduced
- ras G12D/+ x /Wyc OE x Trp53' 1 ' organoids were generated by a cre-mediated recombination of loxp sequences in Kras LSL x Trp53 m colonoids (Lipofectamine-mediated transfection of ere) and transposonbased integration of ectopically expressed, oncogenic Myc.
- a constitutive active Braf mutation Ape 1 ' x Trp53' !
- tumor digestion medium supplemented with 100 pg/ml DNasel and 10.5 pM Y-27632 dihydrochloride (Invitrogen). Tumor digestion was performed at 37°C on a shaker with 75 rpm rotation. The digestion was stopped by adding medium containing 10% FCS (table 3). The mixture was centrifuged for 5 mins at 300 g. Red blood cells were removed by incubating the pellet with ACK lysing buffer (Thermo Fisher) for 5 mins at RT.
- ACK lysing buffer Thermo Fisher
- the pellet was resuspended in medium and, after final centrifugation, the cells were adjusted to roughly 1000 cells in 50 pl Growth Factor Reduced (GFR) MatrigelTM (Corning) and plated in pre-warmed 24-well plates.
- GFR Growth Factor Reduced
- the ascites material was pelleted by centrifugation at 300 g and washed several times with ice-cold PBS before embedding the cells in domes of MatrigelTM (Corning).
- the human CRC medium was supplemented with 10.5 pM Y- 27632 dihydrochloride (Invitrogen). The medium was refreshed every two to three days.
- Confluent organoids were split in splitting medium (Table 3) by mechanical dissociation into smaller cell clumps and replated in MatrigelTM (Corning) domes. Depending on the organoid culture the splitting ratio was 1 :2 to 1 :6 (once or twice per week).
- Nicotinamide I M 10 mM Sigma Aldrich
- Nicotinamide I M 10 mM Sigma Aldrich
- Nicotinamide I M 10 mM Sigma Aldrich
- organoids were mechanically dissociated and digested using TrypLE supplemented with 100 pg/ml DNasel and 10.5 pM Y-27632 dihydrochloride (Invitrogen) at 37°C. 1000 single cells per well were plated in all-white 96 well plates (Greiner) in culture medium (table 3) containing 10% Growth Factor Reduced (GFR) MatrigelTM (Corning). The treatment with different p38a inhibitors or corresponding amounts of DMSO was started after 24 hours. To analyze the treatment response, ATP level were measured 96 hours after treatment start using Cell-Titer Glo2.0 reagent (Promega) according to the manufacturers’ instructions. Results were normalized to vehicle (DMSO). Each assay was performed in three technical and biological replicates. The results are contained in the following table 4.
- the flourescence polarization assay protocol for target residence time determination was recently also published by our group from Pantsar er al., Nature Communications 13, article number: 569 (2022); https://doi.org/10.1038/s41467-022-28164-4.
- the assay adapted a commercially available fluorescence polarization assay kit (Transcreener ADP, BellBrook Labs).
- the compounds were preincubated in 50 mM Tris [pH 7.5], 1 mM dithiothreitol, 10 mM MgCI2, 10 mM p-glycerophosphate, and 0.1 mM NasVC at a concentration of 20-fold IC50 with p38 MAPK (12.4 pg/mL) at room temperature for 1 h to enable the formation of an enzyme- inhibitor-complex. Then the formed complex was “jump diluted” 1 :100 (0.5 pL were diluted into 49.5 pL) in a 96 half area well plate with ATF2 (82 pM) as kinase substrate, ATP (40 pM) and ADP Kinase assay detection reagents.
- the plate was immediately measured every 3 min for 4 h. Fluorescence polarization was detected using the plate reader VictorNivo by PerkinElmer. The assay was performed in triplicates. The obtained data were analyzed via integrated rate equation in Graphpad Prism version 7.0.0. for Windows (GraphPad Software, San Diego, CA, USA). The residence time in seconds was subsequently calculated by the reciprocal value of the rate constant of the dissociation of the drug-target-complex (k O ff). The results are provided in table 4.
- mice In approved animal experiments tumor size during treatment was determined in a colon cancer model. Further, tumor development and survival of the mice was determined in a colon cancer - liver metastases model. All mice were housed and maintained under pathogen free conditions in accordance with the institutional guidelines of the University Hospital Tuebingen. Subcutaneous injection or splenic seeding of organoids was performed in 8 to 10 weeks old C57BL/6 mice. The corresponding organoids were dissociated into single cells, washed twice with PBS and filtered through a 100 pm mesh. 1x10 5 cells were injected into the left and right flanks or the spleen capsule of mice in a 1 :1 mixture of sterile PBS and growth factor reduced (GFR) MatrigelTM.
- GFR growth factor reduced
- mice were anaesthetized using ketamine (100 mg/kg i.p.) and xylazin (10 mg/kg i.p.) in NaCI and a small laparotomy below the thorax was performed.
- ketamine 100 mg/kg i.p.
- xylazin 10 mg/kg i.p.
- the injection site was washed with pre-warmed H2O.
- the mice were treated with the analgesics Carprofen und Metamizol.
- In vivo treatment studies were performed in randomized groups with 20 mg/kg body weight of compound every day. The drugs were administered P.O.
Abstract
The invention relates to p38 MAP kinase inhibitors of formula (I) as shown in the description for use in the treatment of colorectal cancer. Further, the invention relates to p38 MAP kinase inhibitors specifically mentioned in the description, and a pharmaceutical composition comprising said inhibitors.
Description
p38 MAP Kinase Inhibitors for Use in the Treatment of Colorectal Cancer
The invention relates to p38 MAP kinase inhibitors of formula (I) as shown below for use in the treatment of colorectal cancer.
The role of p38a MAP kinase, which is part of the mitogene activated protein (MAP) kinase family, in the human body and its link to some severe diseases such as rheumatoid arthritis and psoriasis has already been investigated, Clin. Dev. Immunol. 2013, 569751 , J Med Chem 2013, 56(1), 241-253 and Ann. Rheum. Dis. 2008, 67, 909 - 916. Additional useful compounds are, for example, disclosed in WO 2006120010 and WO 2010040843. More recently, p38 MAP kinase was also associated with neurodegenerative diseases, such as Alzheimer, Parkinson, and atherosclerotic diseases. The optimization of the drug-target residence time (TRT) has been in the focus of drug development for quite some time. Optimization of p38a MAP kinase inhibitors has resulted in a longer target residence time (TRT) by developing the novel type l1Z> binding mode, J. Med. Chem. 2017, 60, 19, 8027- 8054 and doctoral thesis Heike Wentsch, Eberhard Karls Universitat Tubingen 2017 as well as doctoral thesis Niklas Walter, Eberhard Karls Universitat Tubingen 2017. Inspite of all efforts, no p38a MAP kinase inhibitor has yet been launched into the market. Even drugs with a very high TRT failed, such as BIRB 796 (doramapimod).
Colorectal cancer (CRC) is currently the 3rd most commonly diagnosed malignancy and the 2nd leading cause of cancer related death worldwide. In 2020, more than 1.8 million new cases and more than 900,000 deaths were reported. Surgical resection or endoscopic excision of localized tumors and polyps represents an efficient therapeutic option for patients. However, around one quarter of colorectal cancers are diagnosed at an advanced stage with a metastatic disease and ~ 20% of cases develop metachronous metastases upon surgical removal of the primary tumor, Lancet 2019;394(10207):1467-80 doi 10.1016/S0140- 6736(19)32319-0.
The therapeutic benefit for patients with advanced und metastatic tumors remains limited. Stage IV colorectal cancer patients that were treated with a combination of Oxaliplatin- and Irinotecan based chemotherapies and monoclonal antibodies directed against VEGFR or EGFR only show a median survival between 2 and 2.5 years, Signal Transduct Target Ther 2020;5(1):22 doi 10.1038/s41392-020-0116-z. Checkpoint blocking antibodies like anti-PD1 or anti-CTLA4 show only a limited activity against colorectal cancer. Only microsatellite
instable tumors (which only account for ~ 3% of all colorectal tumors) eventually respond to checkpoint blocking antibodies, Therap Adv Gastroenterol 2020; 13: 1756284820917527 doi 10.1177/1756284820917527. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer, Nature Cancer 2021 doi 10.1038/s43018-021 - 00247-z.
Overall, novel therapeutic options for patients suffering from advanced colorectal cancer are urgently needed. Due to its role in inflammation, autophagy, oncogenic signaling pathways and the tumor microenvironment, a potential role of p38a in colorectal cancer development was suggested, World J Gastroenterol 2014;20(29):9744-58 doi 10.3748/wjg.v20.i29.9744 and Cancer Letters 265 (2008), 16-26. However, treatment studies in colorectal cancer models with established p38a inhibitors did not lead to an efficient therapeutic strategy that exploit p38a targeting for the treatment of colorectal cancer patients. Although several clinical trials have been conducted to analyze the therapeutic potential of p38a inhibition in different tumor entities, p38a inhibitors have not yet been successful for cancer therapies.
The problem underlying the invention was therefore to provide compounds which are effective in the treatment of colorectal cancer.
Surprisingly, it has now been found that the compounds as defined below are effective in treating colorectal cancer (cancer of the colon and/or rectum). Thus, the problem underlying the invention was solved, according to one embodiment, by the provision of the compounds of formula (I)
or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use in treating colorectal cancer, wherein the variables in formula I have the following meanings:
R1 is -CONR6R7;
R2 is alkyl or halogen;
R3 is H or halogen;
R4 is -L2-R5;
L2 is i— NR6-CO- -NR6-CO-NR6-, or i-CH2CO-;
R5 is selected from phenyl, optionally substituted with 1 or 2 substituents independently selected from halogen, alkoxy and haloalkyl, an aromatic 5- or 6-membered heterocyclic group having 1 or 2 heteroatoms independently selected from N, S and O, and cycloalkyl;
R6 is H or alkyl;
R7 is selected from H, alkyl, alkyl which is substituted with a non-aromatic 5- or 6- membered heterocyclic group having 1 or 2 heteroatoms independently selected from N and O, alkyl substituted with 1 or 2 hydroxy groups and alkyl substituted with hydroxyalkyl-NR6-; wherein here and in any following occasion ■ in the meanings of L2 indicates the attachment to ring C.
The following embodiments relate to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or optical isomer thereof for use in treating colorectal cancer:
In one embodiment, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or optical isomer thereof for use in treating colorectal cancer, wherein the compound has a Target Residence Time (TRT) of at least 500 s, preferably at least 900 s, and in particular at least 1000 s, as determined by a fluorescence polarization assay by directly measuring the ADP formed by p38 MAPK kinase reaction.
In another embodiment, at least one of R2 and R3 is halogen or both of them are halogen. In another embodiment, R2 is halogen and R3 is H or halogen. The halogen in these embodiments is preferably F or Cl, in particular F.
In another embodiment, L2 is ■— NR6-CO- or -NR6-CO-NR6-, in particular ■— NR6-CO-.
In another embodiment, if R5 is an aromatic 5- or 6-membered heterocyclic group, it is preferably pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrimidyl, in particular thienyl or furyl, and more particularly thienyl.
In another embodiment, R5 is selected from phenyl, thienyl or cycloalkyl, in particular cycloalkyl. Cycloalkyl is preferably cyclopropyl.
In another embodiment, L2 is ■— NR6-CO- or -NR6-CO-NR6- and R5 is selected from thienyl or cycloalkyl, preferably cyclopropyl. In another embodiment, L2 is ■— CH2CO and R5 is phenyl.
In another embodiment, R6 is H and R7 is H.
In another embodiment, R6 is H and R7 is alkyl, in particular Ci-Cs-alkyl or alkyl, preferably C2-C4 alkyl, substituted with a saturated non-aromatic 5- or 6-membered heterocyclic group having 2 heteroatoms independently selected from N and O. The non-aromatic 5- or 6- membered heterocyclic group is preferably N-morpholinyl or N-piperazinyl, in particular morpholino-N-C2-C4 alkyl, such as morpholino-N-ethyl.
In another embodiment, R6 is H and R7 is alkyl, in particular Ci-Cs-alkyl.
In another embodiment, R6 is H and R7 is alkyl substituted with 1 or 2 hydroxy groups, such as 2-hydroxyethyl or 2,3-dihydroxypropyl.
In another embodiment, R6 is H and R7 is C2-C4 alkyl which is substituted with with a hydroxy-C2-Cs alkylamino group.
In another embodiment, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use in treating colorectal cancer, wherein the compound is selected from the compounds of table 1 :
Compounds 1 and 4 are preferred. A part of the compounds of formula (I) including their preparation is described in J Med Chem 2013, 56(1), 241-253, J. Med. Chem. 2017, 60, 19, 8027-8054 and doctoral thesis Heike Wentsch, Eberhard Karls Universitat Tubingen 2017 and doctoral thesis Niklas Walter, Eberhard Karls Universitat Tubingen 2017. These publications are incorporated herein by reference in their entirety.
In another aspect, the invention relates to a compound of formula (la) having the formula
or a pharmaceutically acceptable salt, solvate or optical isomer thereof.
Further, the invention also relates to a pharmaceutical composition comprising the compound of formula (la) or a pharmaceutically acceptable salt, solvate or optical isomer thereof, as well as to said compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use in treating cancer, in particular colorectal cancer.
The term “compounds of the invention” as used herein includes the compounds of formula (I) and (la) as well as the pharmaceutically acceptable salts, solvates or optical isomers thereof.
The pharmaceutically acceptable salts of the compounds of the invention are especially acid or base addition salts with pharmaceutically acceptable acids or bases. Examples of suitable pharmaceutically acceptable organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, sulfamic acid, Ci-C4-alkylsulfonic acids, such as methanesulfonic acid, cycloaliphatic sulfonic acids, such as S-(+)-10-camphor sulfonic acid, aromatic sulfonic acids, such as benzenesulfonic acid and toluenesulfonic acid, di- and tricarboxylic acids and hydroxycarboxylic acids having 2 to 10 carbon atoms, such as oxalic acid, malonic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, glycolic acid, adipic acid and benzoic acid. Other utilizable acids are described, e.g., in Fortschritte der Arzneimittelforschung [Advances in drug research], Volume 10, pages 224 ff. , Birkhauser Verlag, Basel and Stuttgart, 1966. Examples of suitable pharmaceutically acceptable organic and inorganic bases are alkali metal hydroxides, such as sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides such as calcium or magnesium hydroxide, ammonium hydroxide, organic nitrogen bases such as dimethylamine, trimethylamine, ethanolamine, diethanolamine, triethanolamine, choline, 2-amino-2-hydroxymethyl-propane- 1 ,3-diol, meglumine, procaine etc. L-arginine, L-lysine, ethylenediamine, or hyd roxyethy I py rrol id i ne .
The invention also includes any tautomeric, crystal and polymorphic form of said compounds and salts and mixtures thereof.
The invention also includes solvates such as hydrates.
The compounds contemplated may contain one or more chiral centers, and exist in different optically active forms such enantiomers and diastereomers.
The invention also refers to the pro-drugs of the compounds of the invention. The term "prodrug" refers to an agent which is converted into the parent drug in vivo by some physiological
chemical process. An example, without limitation, of a pro-drug would be a compound of the present invention in the form of an ester.
Pro-drugs have many useful properties. For example, a pro-drug may be more water soluble than the ultimate drug, thereby facilitating intravenous administration of the drug. A pro-drug may also have a higher level of oral bioavailability than the ultimate drug. After administration, the prodrug is enzymatically or chemically cleaved to deliver the ultimate drug in the blood or tissue. Exemplary pro-drugs include, but are not limited to, compounds with carboxylic acid substituents wherein the free hydrogen is replaced by (Ci-C4)alkyl, (Ci- Ci2)alkanoyloxy-methyl, (C4-Cg)1-(alkanoyloxy)ethyl, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1- (alkoxycarbonyl-oxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)- ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3- phthalidyl, 4-crotono-lactonyl, gamma-butyrolacton-4-yl, di-N,N-(Ci-C2)alkylamino(C2-C3)alkyl (such as p-dimethylaminoethyl), carbamoyl-(Ci-C2)alkyl, N,N-di(Ci-C2)-alkylcarbamoyl-(Ci- C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl. Other exemplary pro-drugs release an alcohol of Formula (I) wherein the free hydrogen of the hydroxyl substituent (e.g., R group contains hydroxyl) is replaced by (Ci-C6)alkanoyloxy-methyl, 1-((Ci-Ce)alkanoyloxy)- ethyl, 1-methyl-1-((Ci-C6)alkanoyloxy)ethyl, (Ci-Ci2)alkoxy-carbonyloxy-methyl, N-(Ci-Ce)- alkoxy-carbonylaminomethyl, succinoyl, (Ci-Ce)alkanoyl, a-amino(Ci-C4)alkanoyl, arylactyl and a-aminoacyl, or a-aminoacyl-a-aminoacyl wherein said a-aminoacyl moieties are independently any of the naturally occurring L-amino acids found in proteins, P(O)(OH)2, - P(O)(O(Ci-Ce)alkyl)2 or glycosyl (the radical resulting from detachment of the hydroxyl of the hemiacetal of a carbohydrate).
The organic moieties mentioned in the above definitions of the variables are collective terms for individual listings of the individual group members. The prefix Cn-Cm indicates in each case the possible number of carbon atoms in the group. As used herein the terms have the following meanings:
The term halogen denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine or chlorine, and most preferably fluorine.
Alkyl is a straight-chain or branched alkyl group which is preferably a Ci-Ce-alkyl group, i.e. an alkyl group having from 1 to 6 carbon atoms, and more preferably a Ci-C4-alkyl group.
Examples of an alkyl group are methyl, ethyl, n-propyl, iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl.
The definition of alkyl is likewise applicable to any group which includes an alkyl group.
Cycloalkyl is a cycloaliphatic radical which is preferably Cs-Cs-cycloalkyl, i.e. a cycloalkyl group having from 3 to 8 carbon atoms and, in particular, 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
An aromatic heterocyclic group is a 5- or 6-membered monocyclic aromatic group having 1 or 2 heteroatoms independently selected from O, N and S. The aromatic heterocyclic group may be bound to the neighboring group via a carbon atom (C-bound) or via a nitrogen heteroatom (N-bound). Examples are:
C-bound, 5-membered, heterocyclic groups:
2-furyl, 3-furyl, 5-furyl, 2-thienyl, 3-thienyl, 5-thienyl, pyrrol-2-yl, pyrrol-3-yl, pyrrol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, isothiazol-3- yl, isothiazol-4-yl, isothiazol-5-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl;
C-bound, 6-membered, heteroaromatic rings: pyridin-2-yl, pyridin-3-yl (3-pyridyl), pyridin-4-yl (4-pyridyl), pyridin-5-yl, pyridazin-3-yl, pyridazin-4-yl, pyridazin-6-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-5-yl;
N-bound, 5-membered, heteroaromatic rings: pyrrol-1-yl, pyrazol-1-yl, imidazol-1-yl.
A non-aromatic 5- or 6-membered heterocyclic group is a saturated group and includes in general 1 or 2 heteroatoms selected from O, N and S. The heterocyclic radicals may be bound via a carbon atom (C-bound) or a nitrogen atom (N-bound). Preferred heterocyclic groups comprise 1 nitrogen atom as ring member atom and optionally 1 further heteroatom as ring members, which are selected, independently of each other from O, S and N. Examples are:
C-bound, 4-membered rings, such as azetidin-2-yl, azetidin-3-yl, oxetan-2-yl, oxetan-3-yl;
C-bound, 5-membered rings, such as tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetrahydropyrrol-2-yl, tetrahydropyrrol-3-yl, tetrahydropyrazol-3-yl, tetrahydro-pyrazol-4-yl;
C-bound, 6-membered rings, such as tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 1,3-dioxan-2-yl, 1,3-dioxan- 4-yl, 1,3-dioxan-5-yl, 1,4-dioxan-2-yl;
N-bound, 4-membered rings, such as azetidin-1-yl;
N-bound, 5-membered rings, such as tetrahydropyrrol- 1-yl (pyrrolidin-1 -yl), tetrahydropyrazol-1-yl;
N-bound, 6-membered rings, such as morpholin-1-yl, piperazin-1 -yl, piperidin-1-yl, hexahydropyrimidin-1-yl, hexahydropyrazin-1-yl (piperazin-1 -yl), hexahydro-pyridazin-1-yl;
Any group containing heteroatoms may contain 1 , 2 or 3 heteroatoms which may be the same or different.
The compounds of the invention are customarily administered in the form of pharmaceutical compositions which comprise at least one compound of the invention, optionally together with an inert carrier (e.g. a pharmaceutically acceptable excipient) and, where appropriate, other drugs. These compositions can, for example, be administered orally, rectally, transdermally, subcutaneously, intraperitoneally, intravenously, intramuscularly or intranasally.
Examples of suitable pharmaceutical compositions are solid medicinal forms, such as powders, granules, tablets, in particular film tablets, lozenges, sachets, cachets, sugar- coated tablets, capsules, such as hard gelatin capsules and soft gelatin capsules, or suppositories, semisolid medicinal forms, such as ointments, creams, hydrogels, pastes or plasters, and also liquid medicinal forms, such as solutions, emulsions, in particular oil-in- water emulsions, suspensions, for example lotions, injection preparations and infusion preparations. In addition, it is also possible to use liposomes or microspheres.
When producing the compositions, the compounds of the invention are optionally mixed or diluted with one or more carriers (excipients). Carriers (excipients) can be solid, semisolid or liquid materials which serve as vehicles, carriers or medium for the active compound.
Suitable carriers (excipients) are listed in the specialist medicinal monographs. In addition, the formulations can comprise pharmaceutically acceptable auxiliary substances, such as wetting agents; emulsifying and suspending agents; preservatives; antioxidants; antiirritants; chelating agents; coating auxiliaries; emulsion stabilizers; film formers; gel formers; odor masking agents; taste corrigents; resins; hydrocolloids; solvents; solubilizers; neutralizing agents; diffusion accelerators; pigments; quaternary ammonium compounds; refatting and overfatting agents; raw materials for ointments, creams or oils; silicone derivatives; spreading auxiliaries; stabilizers; sterilants; suppository bases; tablet auxiliaries, such as binders, fillers, glidants, disintegrants or coatings; propellants; drying agents; opacifiers; thickeners; waxes; plasticizers and white mineral oils. A formulation in this regard is based on specialist knowledge as described, for example, in Fiedler, H.P., Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete [Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields], 4th edition, Aulendorf: ECV-Editio-Cantor-Verlag, 1996.
The compounds of the invention may also be suitable for combination with other therapeutic agents and therapeutic approaches. The invention therefore further relates to a combination comprising a compound of the invention with one or more further therapeutic agents or therapeutic approaches. Suitable agents and approaches for use in combination with the compounds of the invention include for example:
Antineoplastic agents and combinations thereof, such as DNA alkylating agents (for example Cisplatin, Oxaliplatin, Carboplatin, Cyclophosphamide, nitrogen mustards like Ifosfamide, Bendamustine, Melphalan, Chlorambucil, Busulphan, Temozolamide and itrosoureas like Carmustine), antimetabolites (for example Gemcitabine and antifolates such as fluoropyrimidines like 5-Fluorouracil, Capecitabine and Tegafur, Raltitrexed, Methotrexate, Cytosine Arabinoside, and Hydroxyurea), anti-tumor antibiotics (for example anthracyclines like Bleomycin, Doxorubicin, Liposomal doxorubicin, Pirarubicin, Daunomycin, Valrubicin, Epirubicin, Idarubicin, Mitomycin-C, Dactinomycin, Amrubicin and Mithramycin), antimitotic agents (for example vinca alkaloids like Vincristine, Vinblastine, Vindesine and Vinorelbine and taxoids like Taxol and Taxotere and polokinase inhibitors) and topoisomerase inhibitors (for example epipodophyllotoxins like Etoposide and Teniposide, Amsacrine, Irinotecan, Topotecan and Camptothecin), inhibitors of DNA repair mechanisms such as CHK kinase inhibitors (for example Prexasertib), DNA-dependent protein kinase inhibitors (such as Omipalisib, AZD7648), inhibitors of poly (ADP-ribose) polymerase (PARP) (for example Olaparib), Hsp90 inhibitors (such as Tanespimycin and Retaspimycin), inhibitors of ATR
kinase (such as AZD6738, Berzosertib, M1774), ATM kinase (such as AZD0156, AZD1390) and WEE1 kinase (such as Adavosertib, PD0166285).
Agents that inhibit protein-protein interactions (for example Venetoclax, Navitoclax) or the proteasome (for example Bortezomib, Carfilzomib, Ixazomib, Marizomib Delanzomib, Oprozomib)
Agents that inhibit protein phosphorylation (such as Abemaciclib, Acalabrutinib, Adavosertib, Afatinib, Aflibercept, Alectinib, Alisertib, Avapritinib, Axitinib, Berzosertib, Binimetinib, Bosutinib, Brigatinib, Cabozantinib, Capmatinib, Cetuximab, Ceritinib, Cobimetinib, Crizotinib, Dabrafenib, Dacomitinib, Dasatinib, Encorafenib, Entrectinib, Erdafitinib, Erlotinib, Everolimus, Fedratinib, Fostamatinib, Gefitinib, Gilteritinib, Ibrutinib, Imatinib, Lapatinib, Larotrectinib, Lenvatinib, Lorlatinib, LY3295668, Midostaurin, Neratinib, Nilotinib, Nintedanib, Osimertinib, Palbociclib, Panitumumab, Pazopanib, PD0166285, Pemigatinib, Pexidartinib, Ponatinib, Pralsetinib, Prexasertib, Regorafenib, Ribociclib, Ripretinib, Ruxolitinib, Selpercatinib, Selumetinib, Sirolimus, Sorafenib, Sunitinib, Temsirolimus, Trametinib, Tucatinib, Upadacitinib, Vandetanib, Vemurafenib, Zanubrutinib, Zunsemetinib),
Agents that block angiogenesis, such as compounds that inhibit the effects of vascular endothelial growth factor, for example the anti-vascular endothelial cell growth factor antibody Bevacizumab and VEGF receptor tyrosine kinase inhibitors such as Vandetanib, Sorafenib, Regorafenib, Vatalanib, Sunitinib, Axitinib, Pazopanib and Cediranib, compounds such as those disclosed in W097/22596, WO 97/30035, WO 97/32856 and WO 98/13354, and compounds that work by other mechanisms (for example linomide, inhibitors of integrin czvB3 function and angiostatin), or inhibitors of angiopoietins and their receptors (Tie-I and Tie-2), inhibitors of PLGF, inhibitors of delta-like ligand (DLL-4).
Immunotherapeutic approaches to increase the immunogenicity of patient tumor cells (including ex-vivo and in-vivo approaches) such as transfection with cytokines (for example interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor), approaches to decrease T-cell anergy or regulatory T-cell function, approaches that enhance T -cell responses to tumors, such as blocking antibodies to CTLA4 (for example ipilimumab and tremelimumab), B7HI, PD-I (for example BMS-936558 or AMP-514), PD-LI (for example MED14736) and agonist antibodies to CD137 and other immune checkpoint inhibitors, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumor cell lines, approaches using antibodies to tumor associated antigens, and antibodies that deplete target cell types (e.g. unconjugated anti-CD20 antibodies such as Rituximab, radiolabeled anti-CD20 antibodies Bexxar and
Zevalin and anti-CD54 antibody Campath), approaches using anti-idiotypic antibodies, approaches that enhance Natural Killer cell function, and approaches that utilize antibodytoxin conjugates (e.g. antiCD33 antibody Mylotarg), immunotoxins such as Moxetumumab Pasudotox, agonists of toll-like receptor 7 or toll-like receptor 9, cellular immunotherapies for example CAR-T cell therapy, NK cell therapy, CAR-NK cell therapy, tumor-infiltrating lymphocytes, recombinant T cells, vaccinations for example anti-tumor peptide vaccines, mRNA vaccines and dendritic cell vaccines.
Agents that enhance the efficacy of drugs, such as leucovorin.
The combination therapies of the invention may be administered adjunctively. By adjunctive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices. This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as addon therapeutic administration. Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of the invention and at least one further therapeutic agent are within the scope of the current invention. In one embodiment of adjunctive therapeutic administration as described herein, a patient is typically stabilized on a therapeutic administration of one or more of the components for a period of time and then receives administration of another component. The combination therapies of the invention may also be administered simultaneously. By simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, administered simultaneously. Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.
In an embodiment the invention also relates to the use of a compound of the invention for treating colorectal cancer. In another embodiment the invention also relates to the use of a compound of the invention for preparing apharmaceutical composition for treating colorectal cancer.
In an embodiment the invention also relates to a method of treating colorectal cancer which comprises administering an effective amount of a compound of the invention or a composition as defined above to a subject in need thereof.
In an embodiment, the compounds of the invention are administered in a dosage of 5 to 50 mg/kg, in particular 10 to 30 mg/kg, for example 20 mg/kg, of the subject being treated. The compounds can be administered once or several times a day. The compounds are administered up to at least 10 weeks.
SYNTHETIC METHODS
GENERAL:
Chemical synthesis of the compounds of the invention was carried out using commonly applied techniques and general procedures. All starting materials and reagents were of commercial quality and were used without further purification unless otherwise stated. Microwave-assisted reactions were performed in a CEM Discover 908005 System in pressure-sealed glass tubes. Thin layer chromatography (TLC) was carried out on Merck 60 F254 and Macherey Nagel ALUGRAM® Xtra SIL G/UV254 silica plates and were visualized under UV light (254 nm and 366 nm) or developed with an appropriate staining reagent. Preparative column chromatography was carried out with an Interchim Puri Flash 430 or Puri Flash XS420 automated flash chromatography system and were unless otherwise stated performed on normal phase silica gel (Grace Davison Davisil LC60A 20-45 micron or Merck Geduran Si60 63-200 micron).
Analytical Methods and Instrumentation:
NMR: 1H and 13C spectra were recorded on Bruker Avance 200, Bruker Avance 400, Bruker A vance III HD 400 or Bruker Avance III HDX 600 instruments. The samples were dissolved in deuterated solvents and chemical shifts are given in relation to tetramethylsilane (TMS). Spectra were calibrated using the residual peaks of the used solvent.
MS: Mass spectra were obtained using a Advion TLC-MS interface with electron spray ionization (ESI) in positive and/or negative mode. Instrument settings as follows: ESI voltage 3,50 kV, capillary voltage 187 V, source voltage 44 V, capillary temperature 250 °C, desolvation gas temperature 250 °C, gas flow 5 l/min nitrogen.
HRMS: High resolution mass spectra were measured by the mass spectrometry department, Institute of Organic Chemistry, Eberhard Karls University Tuebingen on a Bruker maXis 4G ESI-TOF from Daltonik/Bremen. The instrument was run in ESI+ Mode, settings were as follows: nebulizer gas 1.2 bar, gas flow, 6.0 l/min, source temperature 200 °C, capillary voltage +4500 V, end plate offset -500 V. m/z range from 80 to 1000 m/z.
HPLC (High Performance Liquid Chromatography): Purity of final compounds was determined using an Agilent 1100 Series LC with Phenomenex Luna C8 columns (150 x 4.6 mm, 5 pm) and detection was performed with a UV DAD at 254 nm and 230 nm wavelength. Elution was carried out with the following gradient: 0.01 M KH2PO4, pH 2.30 (solvent A), MeOH (solvent
B), 40 % B to 85 % B in 8 min, 85 % B for 5 min, 85 % to 40 % B in 1 min, 40 % B for 2 min, stop time 16 min, flow 1 .5 ml/min. All final compounds showed a purity above 95% in the means of area percent at the two different wavelengths.
Abbreviations:
BrettPhosPdG3 [(2-di-Cyclohexylphosphino-3,6-dimethoxy-2',4',6'- tri isopropyl- 1 , 1 biphenyl)-2-(2'-amino-1 ,1 '-biphenyl)]palladium(ll)-methanesulfonate
DCM dichloromethane
DIPEA diisopropylethylamine DMAP dimethylaminopyridine DMF dimethylformamide DMSO dimethylsulfoxide
EA, EtOAc ethylacetate iPrOH isopropanol mCPBA m-chloroperoxybenzoic acid MeCN acetonitrile
MeOH methanol
Pd(dppf)Ch (1 ,1 '-Bis(diphenylphosphino)ferrocene)palladium(l I) dichloride
TBAF tetrabutylammonium fluoride
TBTLI 2-(1 H-benzotriazole-1-yl)-1 ,1 ,3,3-tetramethylaminium tetrafluoroborate
THF tetrahydrofurane
TLC thin layer chromatography
TsCI tosylchloride tBuOH tert-butanol
Experimental Procedures:
The compounds of the invention can be prepared by the synthetic procedures described in J Med Chem 2013, 56(1), 241-253, J. Med. Chem. 2017, 60, 19, 8027-8054, doctoral thesis Heike Wentsch, Eberhard Karls Universitat Tubingen 2017 and doctoral thesis Niklas Walter, Eberhard Karls Universitat Tubingen 2017 or analogous procedures. As examplary procedures given in these publications the synthesis of compounds 1 and 4 (see table 1) is described in detail as follows:
Compound No. 1 :
8-((3-(Cyclopropanecarboxamido)-4-fluorophenyl)amino)-N-methyl-5-oxo-10,11- dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamide
In an oven dried schlenk tube was dried Tetrabutylammoniumchloride (336 mg, 1.21 mmol, 0.1 eq) by heating under vacuum. Under argon atmosphere were added dimethyl 4- bromoisophthalate (3.31 g, 12.1 mmol, 1.0 eq), /V,/V-dicyclohexyl methylamine (3.54 g, 18.15 mmol, 1.5 eq), 3-chloro styrene (1.84 g, 13.31 mmol, 1.1 eq) and 20 mL dry dioxane. The mixture was degassed carefully with three vacuum/argon cycles before tri-tert- butylphosphonium tetrafluoroborate (140 mg, 484 pmol, 0.04 eq) and tris(dibenzylideneacetone)dipalladium(0) (111 mg, 121 pmol, 0.01 eq) were transferred with additional 5 mL of dry dioxane to the reaction vessel. The mixture was degassed again and was then heated up to 70 °C oil bath temperature. Reaction control via HPLC indicated complete conversion after six hours of stirring. The resultant green suspension was poured on 1M aqueous KHSO4 solution followed by extraction with ethyl acetate (2 x 50 mL). The combined extracts were washed with brine, dried over Na2SO4 and concentrated to almost dryness under reduced pressure. At the onset of crystallization, evaporation was stopped and the resultant slurry was triturated with cyclohexane. The solids were isolated by vacuum filtration washed with additional cyclohexane and dried in vacuo. Yield: 3.78 g (95%) as white amorphous solid. 1H NMR (400 MHz, DMSO) 5 8.37 (d, J = 1.7 Hz, 1 H), 8.11 (dd, J = 8.3, 1.7 Hz, 1 H), 7.98 (d, J = 8.3 Hz, 1 H), 7.91 (d, J = 16.4 Hz, 1 H), 7.65 - 7.60 (m, 1 H), 7.59 - 7.53 (m, 1 H), 7.44 (t, J = 7.8 Hz, 1 H), 7.40 - 7.35 (m, 1 H), 7.32 (d, J = 16.4 Hz, 1 H), 3.90 (s, 3H), 3.88 (s, 3H); 13C NMR (100 MHz, DMSO) 5 166.2, 165.1 , 141.9, 138.8, 133.6, 132.2, 131.7, 131.0, 130.5, 128.7, 128.4, 128.0, 127.3, 127.2, 126.4, 125.3, 52.4, 52.2; HPLC tret = 9.92 min.
S2
In an oven dried schlenk flask were suspended S1 (3.49 g, 10.55 mmol, 1.0 eq) and 175 mg palladium on activated carbon (10% Pd on C) in 105 ml EtOAc (30 mL/g). The stirred mixture was cooled with an ice bath and the catalyst was saturated with hydrogen by bubbling through the suspension for 5 min. The flask was sealed and a hydrogen balloon was attached at the schlenk port to ensure a slightly positive pressure of hydrogen during the reaction. The ice bath was allowed to melt and the internal temperature should be maintained just below 20 °C to avoid hydrodehalogenation. The conversion was monitored via TLC (hexane/THF 4:1) until complete consumption of starting material (overnight stirring necessary at this scale). The catalyst was removed by filtration over a bed of celite and was thoroughly washed with EtOAc. To remove the aliphatic inpurities of the previous step the filtrate was washed successively with 2 M KHSO4 (3x30 mL), water (30 mL), sat. NaHCOs (30 mL) and brine (30 ml). The organic phase was dried over Na2SO4, concentrated under reduced pressure and coevaporated several times with MeOH and DCM to remove traces of water. Yield: 3.07 g (87 %) as a clear viscous oil which crystallizes upon standing. 1H NMR (400 MHz, DMSO) 5 8.36 (d, J = 1.8 Hz, 1 H), 8.04 (dd, J = 8.0, 1.8 Hz, 1 H), 7.51 (d, J = 8.0 Hz, 1 H), 7.33 - 7.27 (m, 2H), 7.26 - 7.22 (m, 1 H), 7.17 - 7.13 (m, 1 H), 3.86 (s, 6H), 3.27 - 3.19 (m, 2H), 2.87 - 2.79 (m, 2H); 13C NMR (100 MHz, DMSO) 5 166.3, 165.3, 147.8, 143.6, 132.8, 132.2, 131.7, 130.9, 130.0, 129.6, 128.1 , 127.7, 127.0, 125.9, 52.2, 52.2, 36.3, 35.3; HPLC tret = 10.03 min.
Under argon atmosphere was added S2 (3.04 g, 9.13 mmol) to 15 ml Eaton’s reagent (5 mL/g) at ambient temperature. The flask was evacuated and backfilled with argon three times while stirring before the mixture was heated up to 80 °C oil bath temperature. After stirring overnight, reaction control indicated complete conversion. The reaction mixture was added dropwise to 150 ml water, which resulted in agglomeration of a brown sticky mass at the stirring bar. The supernatant was decanted off and the residue was triturated with MeOH I water (1 :1) to produce a crystalline solid. The crude product was filtered off, dried in vacuo and recrystallized from MeOH to yield 2.11 g (77 %) of the title compound as beige crystalline solid. 1H NMR
(400 MHz, DMSO) 68.43 (s, 1 H), 8.03 (d, J = 7.9 Hz, 1 H), 7.89 (d, J = 8.3 Hz, 1 H), 7.56 - 7.31 (m, 3H), 3.87 (s, 3H), 3.26 - 3.05 (m, 4H); 13C NMR (100 MHz, DMSO) 5 192.2, 165.4, 147.2, 144.2, 137.6, 137.4, 136.1 , 132.6, 132.3, 131.1 , 130.4, 129.1 , 128.1 , 126.7, 52.2, 33.8, 33.3; HPLC t = 7.96 min.
S4
A screw-top reaction vial was charged with S3 (0.8 g, 2.65 mmol), MeOH (4 mL) and aqueous MeNH2 solution (40%wt, 8 mL at ambient temperature. The mixture was stirred at 50°C oilbath temperature until TLC indicated complete conversion. The reaction was diluted with water and cooled in an ice bath. The resulting precipitate was collected by filtration and washed with water. The filtercake was dried in a convection oven at 60°C to yield the crude title compound as off-white solid. The material was stirred in MeCN at 60°C oil-bath temperature for about two hours and was then filltered and dried to obtain the pure product as white solid. Yield: 0.46 g (58%). 1H NMR (400 MHz, DMSO) 5 8.64 - 8.51 (m, 1 H), 8.36 (d, J = 1.9 Hz, 1 H), 7.96 (dd, J = 7.9, 1.9 Hz, 1 H), 7.90 (d, J = 8.5 Hz, 1 H), 7.49 (d, J = 1.9 Hz, 1 H), 7.48 - 7.35 (m, 2H), 3.27 - 3.13 (m, 4H), 2.79 (d, J = 4.5 Hz, 3H). 13C NMR (101 MHz, DMSO) 5 192.9, 165.6, 144.8, 144.3, 137.4, 137.3, 136.4, 132.9, 132.2, 131.0, 129.9, 129.3, 129.0, 126.8, 33.6, 33.5, 26.3. TLC-MS (ESI) m/z = 354.6 [M+Na+MeOH]+ HPLC tret = 9.19 min.
S5.1
2-Fluoro-5-nitroaniline (1.26 g, 8.07 mmol) was dissolved in DCM (40 mL) and pyridine (0.85 mL) was added to the stirred solution. Then cyclopropane carbonylchloride (0.88 mL) was added in one portion and stirring was continued until TLC indicated complete conversion (about 90 min). The reaction was diluted with DCM and washed with 2N HCI and sat. NaHCOs. The organic phase was dried, evaporated and the crude product was triturated with pentane and a small amount of DCM. After aging in the freezer, the precipitate was isolated by filtration and washed with cold pentane. After drying in vacuo, the title compound was yielded as off- white crystalline solid. Yield: 1.73 g (96%). 1H NMR (400 MHz, DMSO) 5 10.41 (s, 1 H), 9.01
(dd, J = 6.8, 3.0 Hz, 1 H), 7.99 (ddd, J = 9.1 , 4.1 , 3.0 Hz, 1 H), 7.55 (dd, J = 10.3, 9.1 Hz, 1 H), 2.19 - 2.00 (m, 1 H), 0.96 - 0.78 (m, 4H). 13C NMR (101 MHz, DMSO) 5 173.0, 155.9 (d, J = 255.5 Hz), 143.7 (d, J = 2.6 Hz), 127.5 (d, J = 13.2 Hz), 119.8 (d, J = 9.5 Hz), 117.8 (d, J = 4.2 Hz), 116.5 (d, J = 22.5 Hz), 14.1 , 8.0. TLC-MS (ESI) m/z = 222.9 [M-H]’ HPLC tret = 5.77 min.
To a stirred solution of S5.1 (1.7 g, 7.58 mmol) in THF/EtOAc/MeOH (1 :1 :1 , 50 mL) was added Pd/C (100 mg) and hydrogen was bubbled through the solution for about fifteen minutes. Then the flask was sealed and a hydrogen balloon was attached to the reaction vessel. Stirring was continued overnight at ambient temperature. TLC indicated complete conversion at this point and the catalyst was filtered off and washed with EtOAc and MeOH. The filtrate was concentrated to a yellowish oil, which was layered with hexane and agitated under ice-cooling until precipitation of a white solid occured. The precipitate was triturated with hexane and a small amount of DCM and aged in the freezer for about one hour. The product was isolated by filtration, washed with cold hexane and dried in vacuo. HPLC indicated contamination with a not further characterized side product and therefore the crude product was purified via flash chromatography (DCM I MeOH 1-5%). The pure title compound was obtained as white solid. Yield: 1.24 g (84%). 1H NMR (400 MHz, DMSO) 5 9.65 (s, 1 H), 7.13 (d, J = 4.5 Hz, 1 H), 6.85 (dd, J = 10.8, 8.8 Hz, 1 H), 6.33 - 6.16 (m, 1 H), 4.91 (br s, 2H), 2.04 - 1.87 (m, 1 H), 0.85 - 0.65 (m, 4H). 13C NMR (101 MHz, DMSO) 5 171.8, 145.7 (d, J = 232.5 Hz), 144.9 (d, J = 1.4 Hz), 126.1 (d, J = 12.5 Hz), 115.0 (d, J = 20.2 Hz), 109.4 (d, J = 6.2 Hz), 109.3 - 109.1 (m), 14.0, 7.2. TLC-MS (ESI) m/z = 249.4 [M+Na+MeOH]+ HPLC tret = 1 .47 min.
Step 6: 8-((3-(Cyclopropanecarboxamido)-4-fluorophenyl)amino)-N-methyl-5-oxo-10,11- dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamide (1)
In a 50 mL schlenk-flask were combined S4 (0.5 g, 1.67 mmol), S5.2 (0.32 g 1 .67 mmol) and CS2CO3 (1.09 g. 3.35 mmol) and degassed dioxane/tBuOH (4:1 , 20 mL) was added subsequently. The suspension was further degassed with five vacuum/argon cycles, then BrettPhos Pd G3 (8 mg, 9 pmol) was added and the degassing procedure was repeated again.
The flask was sealed and heated to 90°C oil-bath temperature. TLC indicated complete conversion after two hours and therefore the reaction was cooled to ambient temperature, diluted with EtOAc and transferred to a separatory funnel with half-sat. NaCI. After shaking and separating, the aqueous phase was extracted once more with EtOAc (40ml) and the combined extracts were washed with brine prior to drying over Na2SO4 and evaporation. The crude product was taken up in 7.5 ml MeOH, resulting in the precipitation of a yellow solid. The suspension was heated to 60°C oil-bath temperature under stirring for one hour. The suspension was cooled first to ambient temperature then for 30 min in an ice-bath. The solids were collected by filtration, washed with chilled MeOH and dried in a vacuum oven at 60°C to yield the title substance as bright yellow solid. Yield: 0.70 g (92%). 1H NMR (400 MHz, DMSO) 5 10.02 (s, 1 H), 8.84 (s, 1 H), 8.55 (q, J = 4.2 Hz, 1 H), 8.33 (d, J = 1.9 Hz, 1 H), 8.01 (d, J = 8.9 Hz, 1 H), 7.90 (dd, J = 7.9, 1.9 Hz, 1 H), 7.89 - 7.83 (m, 1 H), 7.40 (d, J = 8.0 Hz, 1 H), 7.21 (dd, J = 10.7, 8.9 Hz, 1 H), 6.97 - 6.90 (m, 2H), 6.82 (d, J = 2.1 Hz, 1 H), 3.15 - 3.02 (m, 4H), 2.78 (d, J = 4.5 Hz, 3H), 2.08 - 1.98 (m, 1 H), 0.85 - 0.76 (m, 4H). 13C NMR (101 MHz, DMSO) 5 190.2, 172.2, 165.9, 148.7, 148.6 (d, J = 240.1 Hz), 145.3, 144.4, 138.9, 133.4, 130.2, 129.0, 128.9, 127.1 (d, J = 1.8 Hz), 126.8 (d, J = 12.6 Hz), 116.0 (d, J = 7.0 Hz), 115.7 (d, J = 20.7 Hz), 115.5 (d, J = 1.7 Hz), 113.9, 112.5, 35.4, 33.7, 26.2, 14.0, 7.4. TLC-MS (ESI) m/z = 480.2 [M+Na]+. HRMS (ESI) [M+Na]+ calcd for C27H24FN3NaO3+, 480.16939; found 480.16984. HPLC tret = 7.11 min.
Compound no. 4 8-((3-(3-Cyclopropylureido)-4-fluorophenyl)amino)-N-methyl-5-oxo-10,11-dihydro-5H- dibenzo[a,d][7]annulene-3-carboxamide (4).
4.1
2-Fluor-5-nitroaniline (0.78 g, 5.0 mmol) was dissolved in dioxane (20 mL) at ambient temperature and pyridine (0.40 mL) was added subsequently. Phenylchloroformate (0.63 mL) was added dropwise as solution in dioxane under vigorous stirring, resulting in formation of a precipitate. After about 15 min, TLC indicated complete conversion to the carbamate
intermediate and cyclopropylamine (1.04 mL) was added slowly. The flask was placed in an oil-bath at 80°C and stirring was continued until TLC indicated complete consumption of the phenyl carbamate (about 2 hours). After cooling to ambient temperature, the mixture was diluted with EA and the organic phase was successively washed with water, 1 M NaOH (2x), 2N HCI and brine. The organic phase was dried over Na2SO4 and evaporated. The yellow residue was recrystallized from MeOH to obtain the pure title compound as pale yellowish solid. Yield: 0.76 g (64%). 1H NMR (200 MHz, DMSO) 5 9.10 (dd, J = 7.0, 2.8 Hz, 1 H), 8.59 (d, J = 1.8 Hz, 1 H), 7.88 - 7.73 (m, 1 H), 7.53 - 7.34 (m, 1 H), 6.93 (d, J = 1.9 Hz, 1 H), 2.63 - 2.51 (m, 1 H), 0.72 - 0.58 (m, 2H), 0.48 - 0.30 (m, 2H). 13C NMR (50 MHz, DMSO) 5 155.3,
154.7 (d, J = 251.8 Hz), 144.0 (d, J = 2.4 Hz), 129.4 (d, J = 12.2 Hz), 117.0 (d, J = 9.3 Hz),
115.8 (d, J = 22.2 Hz), 114.4 (d, J = 4.3 Hz), 22.3, 6.3. TLC-MS (ESI) m/z = 262.2 [M+Na]+ HPLC t = 5.56 min.
To a solution of 4.1 (1.27 g, 5.31 mmol) in EtOAc (15 mL) and THF (15 mL) was added Pd/C (120 mg) and the mixture was purged with hydrogen for several minutes. The flask was sealed and the reaction was stirred under hydrogen overnight at ambient temperature. HPLC indicated complete conversion after about 24 hours. The catalyst was filtered off, washed with EA and the filtrate was evaporated under reduced pressure. The title compound was obtained as off-white solid. Yield: 1.08 g (97%). 1H NMR (200 MHz, DMSO) 5 7.79 (d, J = 1.8 Hz, 1 H), 7.35 (dd, J = 7.2, 2.6 Hz, 1 H), 6.84 - 6.67 (m, 2H), 6.13 - 5.98 (m, 1 H), 4.82 (br s, 2H), 2.57 - 2.47 (m, 1 H), 0.68 - 0.54 (m, 2H), 0.42 - 0.28 (m, 2H). 13C NMR (50 MHz, DMSO) 5 155.9, 145.4 (d, J = 1.7 Hz), 144.6 (d, J = 227.9 Hz), 128.3 (d, J = 11.3 Hz), 114.7 (d, J = 19.7 Hz), 106.7 (d, J = 6.8 Hz), 106.1 (d, J = 1.1 Hz), 22.6, 6.6. TLC-MS (ESI) m/z = 232.2 [M+Na]+ HPLC t = 1.42 min.
Step 3: 8-((3-(3-Cyclopropylureido)-4-fluorophenyl)amino)-N-methyl-5-oxo-10,11-dihydro-5H- dibenzo[a,d][7]annulene-3-carboxamide 4.
A suspension of S4 (0.6 g, 2.0 mmol) and 92.2 (0.42 g, 2.0 mmol) in dioxane I tBuOH (4:1 , 20 mL) was degassed via several vacuum/argon cycles. Then BrettPhos Pd G3 (9 mg) was added
as suspension in dioxane I tBuOH followed by addition of NaOtBu as solution in THF (2M, 3.5 mL). The degassing procedure was repeated, the flask was sealed and placed in an oil-bath at 80°C. TLC indicated complete conversion after 90 min and the reaction was quenched by dilution with EtOAc I dioxane (40 ml each) and addition of water. The organic phase was sequentially washed with half-sat. NaCI and sat. NaCI, dried over Na2SO4 and evaporated under reduced pressure.
The solid residue was taken up in 12 ml aqueous MeCN (90% v/v) and stirred at 60°C for one hour. Then the suspension was slowly cooled to ambient temperature and finally cooled in an ice-bath for 30 min. The solids were isolated by filtration and the filtercake was washed with additional aqueous MeCN. The product was dried in a vacuum oven at 60°C for 48 hours. Yield: 0.82 g (87%). 1H NMR (400 MHz, DMSO) 5 8.79 (s, 1H), 8.54 (q, J = 4.2 Hz, 1 H), 8.33 (d, J= 1.8 Hz, 1H), 8.19 - 8.12 (m, 1H), 8.08 (dd, J= 7.3, 2.6 Hz, 1H), 8.01 (d, J= 8.8 Hz, 1 H), 7.90 (dd, J = 7.9, 1.9 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1 H), 7.14 (dd, J = 11.1 , 8.8 Hz, 1 H), 6.95 (dd, J = 8.8, 2.2 Hz, 1 H), 6.86 - 6.79 (m, 2H), 6.78 - 6.70 (m, 1 H), 3.20 - 2.98 (m, 4H), 2.79 (d, J = 4.5 Hz, 3H), 2.59 - 2.52 (m, 1H), 0.69 - 0.58 (m, 2H), 0.44 - 0.33 (m, 2H). 13C NMR (101 MHz, DMSO) 5 190.2, 166.0, 155.5, 149.0, 147.3 (d, J = 236.5 Hz), 145.4, 144.5, 139.0, 137.1 (d, J = 2.1 Hz), 133.5, 132.8, 130.2, 129.1 , 128.9, 128.7 (d, J = 11.4 Hz), 126.8, 115.2 (d, J = 20.2 Hz), 113.9, 113.1 (d, J = 7.1 Hz), 112.5, 112.3 - 112.0 (m), 35.5, 33.8, 26.3, 22.3, 6.3. TLC-MS (ESI) m/z = 495.3 [M+Na]+. HRMS (ESI) [M+Na]+ calcd for C27H25FN4NaO3+, 495.18029; found 495.18060. HPLC tret = 7.16 min.
Compounds of formula (I), wherein L2 is ■— CH2CO-, can be prepared as exemplified in the following reaction scheme 4 according to conventional procedures. Conversion to the final products can be carried out according to the procedures given in J. Med. Chem. 2013, 56(1), 241-253, J. Med. Chem. 2017, 60, 19, 8027-8054, doctoral thesis Heike Wentsch, Eberhard Karls Universitat Tubingen 2017 and doctoral thesis Niklas Walter, Eberhard Karls Universitat Tubingen 2017 or analogous procedures. The reaction scheme is illustrated below for two reaction sequences leading to intermediates for preparing compounds of formula (I), wherein L2 is ■— CH2CO- and R5 is phenyl or thienyl.
Reaction scheme 1
Ketone derivatives were accessible via one of the above depicted synthetic routes starting from the 3-nitro phenylacetic acid derivatives or 3-nitro benzoic acid derivatives using either an activation to the acid chloride and a subsequent Friedel-Crafts acylation or the transformation to the corresponding Weinreb amide and subsequent reaction with organometallic reagents. The aniline for Buchwald-Hartwig was then obtained by reduction of the nitro group using state of the art reductive methods like tin(ll)chloride in ethanol or elemental hydrogen in combination with palladium on charcoal.
The exemplary preparation of two derivatives of this class of residues is described in detail below:
A solution of 2,4-difluoro-5-nitrophenylacetic acid (4.71 g, 20 mmol) in thionyl chloride (40 mL) and a catalytic amount of DMF was refluxed for 2 hours. The volatiles were removed under reduced pressure and the residue was co-evaporated twice with dry toluene. The crude acid chloride as obtained in quantitative yield and was used directly in the next step without further purification.
To a solution of AlC (1.27 g, 9.5 mmol) in benzene (50 mL) was added dropwise A.1 (1.50 g, 6.4 mmol) under cooling conditions. After TLC indicated complete conversion, the reaction was poured on ice and 6M HCL was added. The aqueous phase was extracted with DCM (3 x 30
mL), the combined extracts were washed with water dried over Na2SO4 and evaporated to dryness to obtain the title substance as yellow crystalline solid. Yield: 1.06 g (83%). 1H-NMR (200 MHz, CDCh) 5 8.12 - 8.04 (m, 2H), 7.75 - 7.44 (m, 3H), 7.11 (dd, J = 10.3, 9.0 Hz, 2H), 4.43 (s, 2H).
To a solution of A.2 (1.0 g 3.6 mmol) in 30 mL EtOH was added SnCh dihydrate (4.06 g, 18 mmol) and the reaction was heated to reflux until TLC indicated complete conversion. Solid NaHCCh (6 g) was added to the stirred solution and subsequently the majority of EtOH was removed under reduced pressure. The residue was triturated with EtOAc and filtered over celite. The filtrate was evaporated to obtain the title substance as brownish solid. Yield: 0.86 g (96%). 1H-NMR (200 MHz, CDCh) 6 8.05 - 7.97 (m, 2H), 7.63 - 7.42 (m, 3H), 6.79 (dd, J = 10.6, 9.4 Hz, 1 H), 6.64 (dd, J = 9.6, 7.4 Hz, 1 H), 4.19 (s, 2H), 3.38 (s, 2H).
To a solution of /\/,O-dimethylhydroxylamine hydrochloride (91 mg, 0.94 mmol) and Et3N (172 mg, 1 ,70 mmol) in DCM (5 mL) was added A.1 (200 mg, 0.85 mmol) dropwise under ice cooling. After TLC indicated complete conversion, water was added and the aqueous phase was extracted with DCM (3 x 15 mL). The combined extracts were washed with brine and evaporated to dryness to obtain the title substance as yellow solid. Yield: 200 mg (90%). 1H- NMR (400 MHz, CDCh) 6 8.10 (t, J = 7.8 Hz, 1 H), 7.03 (dd, J = 10.4, 9.0 Hz, 1 H), 3.84 (s, 2H), 3.77 (s, 3H), 3.23 (s, 3H).
A three necked flask was charged with magnesium turnings (129 mg, 5.38 mmol) and THF (8 mL) under argon atmosphere. To this was added a small portion of a solution of 2-
bromothiophene (877 mg, 5.38 mmol) in THF (3 mL). Upon onset of the reaction indicated by formation of turbidity, the residual amount of the solution was added slowly in a rate that kept the exothermic reaction under control. Stirring was continued for one hour at ambient temperature, before it was cooled in an ice bath and a solution of B.1 (700 mg, 2.69 mmol) in THF (8 mL) was added slowly. After stirring overnight at ambient temperature, aqueous NH4CI was added and the mixture was extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified via flash chromatography to obtain the title compound as yellow solid. Yield: 67 mg (9%). 1H-NMR (400 MHz, CDCh) 6 8.12 (t, J = 7.8 Hz, 1 H), 7.85 (dd, J = 3.8, 1.1 Hz, 1 H), 7.73 (dd, J = 5.0, 1.1 Hz, 1 H), 7.20 (dd, J = 4.9, 3.9 Hz, 1 H), 7.07 (dd, J = 10.3, 9.0 Hz, 1 H), 4.30 (s, 2H).
The preparation of this compound was performed like described above for compound A.3 starting from 83 mg B.2 and yielding 59 mg (81 %) of the desired product B.3 as yellowish oil. 1H-NMR (200 MHz, CDCh) 6 7.79 (d, J = 3.3 Hz, 1 H), 7.65 (d, J = 4.8 Hz, 1 H), 7.13 (t, 1 H), 6.85 - 6.62 (m, 2H), 4.11 (s, 2H), 3.58 (bs, 2H).
Compounds of the invention obtained according to the above-mentioned procedures are given in the following table 2.
Generation of murine and human organoid cultures
Murine colon organoids were isolated from genetically modified mice as described before (Sato et al., Nature 459, 262-265, 2009). The tissue fragments were washed with ice-cold PBS (phosphate buffered saline), transferred to 2 mM EDTA chelating buffer and incubated for 30 mins at 4°C on an orbital shaker. Subsequently, the supernatant was removed and the tissue fragments were resuspended in medium containing 10% FCS (Fetal Calf Serum, table 3). The supernatant containing crypts were centrifuged at 150 g for 5 mins and colonic crypts were embedded in 50 pl domes of Growth Factor Reduced (GFR) MatrigelTM (Corning) in 24-well plates. Following polymerization for 10 mins at 37°C, MatrigelTM (Corning) domes were overlaid with murine colon medium (table 3), supplemented with 10.5 pM Y-27632 dihydrochloride (Invitrogen) for the three days.
To generate a rasG12D;Apc+A; Trp53'A (KAP) CRC organoid culture which was predominantly used to test different p38a inhibitors (Table 4), untransformed colonoids were transformed into a CRC culture in vitro by CRISPR/Cas9-mediated gene editing of Ape and cre-mediated recombination of the floxed rasG12D and Trp53 alleles.
To test the most efficient p38a compounds in CRC organoid cultures with different genetic backgrounds, additional murine CRC organoid cultures were generated. rasG12D/+ x /WycOE x Trp53'1' organoids were generated by a cre-mediated recombination of loxp sequences in KrasLSL x Trp53m colonoids (Lipofectamine-mediated transfection of ere) and transposonbased integration of ectopically expressed, oncogenic Myc. To generate CRC organoids, with a constitutive active Braf mutation (Ape1' x Trp53'!'x Braf*600^, a full loss of Ape and Trp53 was induced through cre-mediated recombination (Ape) or CRISPR/Cas9-mediated (Trp53) gene knockout followed by a retroviral delivery of ectopically expressed Bra^6005. The genetic manipulation of cultures was confirmed by PCR or western blot analyses.
Human CRC organoids were isolated from primary colorectal tumors or ascites material of patients. All patients gave their consent.
Primary tumor material was washed in ice-cold splitting medium and cut into small pieces. The tissue was transferred into tumor digestion medium supplemented with 100 pg/ml DNasel and 10.5 pM Y-27632 dihydrochloride (Invitrogen). Tumor digestion was performed at 37°C on a shaker with 75 rpm rotation. The digestion was stopped by adding medium containing 10% FCS (table 3). The mixture was centrifuged for 5 mins at 300 g. Red blood cells were removed by incubating the pellet with ACK lysing buffer (Thermo Fisher) for 5 mins at RT.
Afterwards the pellet was resuspended in medium and, after final centrifugation, the cells were adjusted to roughly 1000 cells in 50 pl Growth Factor Reduced (GFR) MatrigelTM (Corning) and plated in pre-warmed 24-well plates.
The ascites material was pelleted by centrifugation at 300 g and washed several times with ice-cold PBS before embedding the cells in domes of MatrigelTM (Corning).
Within the first week of culture the human CRC medium was supplemented with 10.5 pM Y- 27632 dihydrochloride (Invitrogen). The medium was refreshed every two to three days.
Confluent organoids were split in splitting medium (Table 3) by mechanical dissociation into smaller cell clumps and replated in MatrigelTM (Corning) domes. Depending on the organoid culture the splitting ratio was 1 :2 to 1 :6 (once or twice per week).
All organoid cultures were characterized histologically (staining for the CRC markers Cytokeratin 20 and Cdx2). The genetic background of human CRC cultures was determined by panel sequencing (CeGAT GmbH). Table 3: media used for organoid culture
Splitting medium
Substance Stock concentration Final concentration Company
Gibco™ Advanced DMEM/F- lx lx Thermo Fisher
12
GlutaMAX lOOx lx Thermo Fisher
HEPES I M 10 mM Thermo Fisher
Primocin™ 50 mg/ml 125 pg/ml Invivogen
Murine colon medium
Substance Stock concentration Final concentration Company
Splitting medium lx lx
B-27® Supplement 50x lx Thermo Fisher
N-2 Supplement lOOx lx Thermo Fisher
Nicotinamide I M 10 mM Sigma Aldrich
N-Acetyl-L-cysteine 500 mM 1.25 mM Sigma Aldrich
Recombinant Murine Noggin 100 pg/ml 100 ng/ml Peprotech
Recombinant Human R- 500 pg/ml 500 ng/ml Peprotech
Spondin-1
EGF Recombinant Mouse 500 pg/ml 50 ng/ml Thermo Fisher
Protein
Recombinant Human Wnt-3a 100 pg/ml 100 ng/ml R&D Systems
Protein
Murine CRC medium
Substance Stock concentration Final concentration Company
Splitting medium lx lx
B-27® Supplement 50x lx Thermo Fisher
N-2 Supplement lOOx lx Thermo Fisher
Nicotinamide I M 10 mM Sigma Aldrich
N-Acetyl-L-cysteine 500 mM 1.25 mM Sigma Aldrich
Recombinant Murine Noggin 100 pg/ml 100 ng/ml Peprotech
Human CRC medium
Substance Stock concentration Final concentration Company
Splitting medium lx lx
B-27® Supplement 50x lx Thermo Fisher
N-2 Supplement lOOx lx Thermo Fisher
Nicotinamide I M 10 mM Sigma Aldrich
N-Acetyl-L-cysteine 500 mM 1.25 mM Sigma Aldrich
Recombinant Murine Noggin 100 pg/ml 100 ng/ml Peprotech
Recombinant Human R- 500 pg/ml 500 ng/ml Peprotech
Spondin-1
Animal-Free Recombinant 50 pg/ml 50 ng/ml Peprotech
Human EGF
Recombinant Human Wnt-3a 100 pg/ml 100 ng/ml R&D Systems
Protein
A83-01 0,5 mM 0,5 pM TOCRIS
Gastrinl 10 pM 10 nM TOCRIS
PGE2 I mM 1 pM R&D Systems
Tumor digestion medium
Splitting medium lx lx
Collagenase II 2,5 mg/ml Thermo Fisher
Collagenase IX 2,5 mg/ml Sigma Aldrich
Dispase ll lmg/ml Sigma Aldrich
Treatment studies in organoid cultures
For the treatment studies, organoids were mechanically dissociated and digested using TrypLE supplemented with 100 pg/ml DNasel and 10.5 pM Y-27632 dihydrochloride (Invitrogen) at 37°C. 1000 single cells per well were plated in all-white 96 well plates (Greiner) in culture medium (table 3) containing 10% Growth Factor Reduced (GFR) Matrigel™ (Corning). The treatment with different p38a inhibitors or corresponding amounts of DMSO was started after 24 hours. To analyze the treatment response, ATP level were measured 96
hours after treatment start using Cell-Titer Glo2.0 reagent (Promega) according to the manufacturers’ instructions. Results were normalized to vehicle (DMSO). Each assay was performed in three technical and biological replicates. The results are contained in the following table 4.
Determination of Target Residence Time
The flourescence polarization assay protocol for target residence time determination was recently also published by our group from Pantsar er al., Nature Communications 13, article number: 569 (2022); https://doi.org/10.1038/s41467-022-28164-4. The assay adapted a commercially available fluorescence polarization assay kit (Transcreener ADP, BellBrook Labs). The compounds were preincubated in 50 mM Tris [pH 7.5], 1 mM dithiothreitol, 10 mM MgCI2, 10 mM p-glycerophosphate, and 0.1 mM NasVC at a concentration of 20-fold IC50 with p38 MAPK (12.4 pg/mL) at room temperature for 1 h to enable the formation of an enzyme- inhibitor-complex. Then the formed complex was “jump diluted” 1 :100 (0.5 pL were diluted into 49.5 pL) in a 96 half area well plate with ATF2 (82 pM) as kinase substrate, ATP (40 pM) and ADP Kinase assay detection reagents. The plate was immediately measured every 3 min for 4 h. Fluorescence polarization was detected using the plate reader VictorNivo by PerkinElmer. The assay was performed in triplicates. The obtained data were analyzed via integrated rate equation in Graphpad Prism version 7.0.0. for Windows (GraphPad Software, San Diego, CA, USA). The residence time in seconds was subsequently calculated by the reciprocal value of the rate constant of the dissociation of the drug-target-complex (kOff). The results are provided in table 4.
Animal studies
In approved animal experiments tumor size during treatment was determined in a colon cancer model. Further, tumor development and survival of the mice was determined in a colon cancer - liver metastases model. All mice were housed and maintained under pathogen free conditions in accordance with the institutional guidelines of the University Hospital Tuebingen. Subcutaneous injection or splenic seeding of organoids was performed in 8 to 10 weeks old C57BL/6 mice. The corresponding organoids were dissociated into single cells, washed twice with PBS and filtered through a 100 pm mesh. 1x105 cells were injected into the left and right flanks or the spleen capsule of mice in a 1 :1 mixture of sterile PBS and growth factor reduced (GFR) Matrigel™. For splenic seeding, mice were anaesthetized using ketamine (100 mg/kg i.p.) and xylazin (10 mg/kg i.p.) in NaCI and a small laparotomy below the thorax was performed. Upon injection into the capsule of the spleen, the injection site was washed with pre-warmed H2O. Within the first week after operation, the mice were treated with the analgesics Carprofen und Metamizol.
In vivo treatment studies were performed in randomized groups with 20 mg/kg body weight of compound every day. The drugs were administered P.O. via oral gavage dissolved in Phosal50PG/Ethanol/PEG400 (60%/10%/30%) or Cremophor/Ethanol/H2O (12.5%/12.5%75%). For cancer treatment studies, the therapies were started after 1 week (subcutaneous KAP tumors and KMP metastases) or 5 weeks (KAP metastases) after tumor initiation. The results are shown in figures 1 and 2 for compound no. 1. Upon treatment with compound no.1 tumor volume remains essentially constant after 12 days of treatment (fig. 1) and survival time of the mice increased significantly (fig. 2).
Claims
1 . A compound of formula I
or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use in treating colorectal cancer, wherein the variables in formula I have the following meanings:
R1 is -CONR6R7;
R2 is alkyl or halogen;
R3 is H or halogen;
R4 is -L2-R5;
L2 is i— NR6-CO-, i-NR6-CO-NR6-, or i-CH2CO-;
R5 is selected from phenyl, optionally substituted with 1 or 2 substituents independently selected from halogen, alkoxy and haloalkyl, an aromatic 5- or 6-membered heterocyclic group having 1 or 2 heteroatoms independently selected from N, S and O, and cycloalkyl;
R6 is H or alkyl;
R7 is selected from
H, alkyl, alkyl which is substituted with 1 or 2 hydroxy groups or with a non-aromatic 5- or 6- membered heterocyclic group having 1 or 2 heteroatoms independently selected from N and O, and alkyl substituted with hydroxyalkyl-NR6-; wherein ■ in the meanings of L2 indicates the attachment to ring C.
2. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to claim 1 , wherein R2 is halogen and R3 is H or halogen.
3. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to claim 1 or 2, wherein R2 is F and R3 is H or F.
4. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to any one of the preceding claims, wherein L2 is ■— NR6-CO- or -NR6-CO-
NR6-, in particular ■— NR6-CO-.
5.. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to any one of claims 1 to 3, wherein L2 is ■— CH2CO.
6. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to any one of the preceding claims, wherein R5 is selected from phenyl, thienyl or cycloalkyl, in particular cyclopropyl.
7. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to any one of claims 1 to 4, wherein L2 is ■— NR6-CO- or -NR6-CO-NR6- and R5 is selected from thienyl or cycloalkyl.
8. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to claim 5, wherein L2 is ■— CH2CO and R5 is selected from phenyl.
9. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to any one of the preceding claims, wherein R7 is alkyl, in particular methyl or ethyl.
10. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to any one of claims 1 to 8, wherein R7 is C2-C4 alkyl which is substituted with a morpholino group or C2-C4 alkyl which is substituted with a hydroxy-C2-Cs alkylamino group.
12. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to any one of the preceding claims, wherein the compound has a Target Residence Time (TRT) of at least 500 s, preferably at least 900 s, and in particular at least 1000 s, as determined by a fluorescence polarization assay by directly measuring the ADP formed by p38 MAPK kinase reaction.
13. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to any one of the preceding claims, wherein the compound is used as a monotherapy.
14. A compound or a pharmaceutically acceptable salt, solvate or optical isomer thereof, for use according to any one of the preceding claims, wherein the compound is used in a dosage of of 5 to 50 mg/kg, in particular 10 to 30 mg/kg.
15. A method for treating colorectal cancer which comprises administering a compound of formula I as defined in any one of claims 1 to 12 or a pharmaceutically acceptable salt, solvate or optical isomer thereof to a subject in need thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22165052.6 | 2022-03-29 | ||
EP22165052 | 2022-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023186881A1 true WO2023186881A1 (en) | 2023-10-05 |
Family
ID=80978810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/057981 WO2023186881A1 (en) | 2022-03-29 | 2023-03-28 | P38 map kinase inhibitors for use in the treatment of colorectal cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023186881A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022596A1 (en) | 1995-12-18 | 1997-06-26 | Zeneca Limited | Quinazoline derivatives |
WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
WO1998013354A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
WO2006120010A2 (en) | 2005-05-12 | 2006-11-16 | Merckle Gmbh | Dibenzocycloheptane compounds and pharmaceuticals containing these compounds |
WO2010040843A2 (en) | 2008-10-09 | 2010-04-15 | C-A-I-R Biosciences Gmbh | Dibenzocycloheptanone derivatives and pharmaceutical agents containing said compounds |
-
2023
- 2023-03-28 WO PCT/EP2023/057981 patent/WO2023186881A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022596A1 (en) | 1995-12-18 | 1997-06-26 | Zeneca Limited | Quinazoline derivatives |
WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
WO1998013354A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Quinazoline derivatives and pharmaceutical compositions containing them |
WO2006120010A2 (en) | 2005-05-12 | 2006-11-16 | Merckle Gmbh | Dibenzocycloheptane compounds and pharmaceuticals containing these compounds |
WO2010040843A2 (en) | 2008-10-09 | 2010-04-15 | C-A-I-R Biosciences Gmbh | Dibenzocycloheptanone derivatives and pharmaceutical agents containing said compounds |
Non-Patent Citations (19)
Title |
---|
"Fortschritte der Arzneimittelforschung", vol. 10, 1966, BIRKHAUSER VERLAG, article "Advances in drug research", pages: 224 |
"Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer", NATURE CANCER, 2021 |
ANN. RHEUM. DIS., vol. 67, 2008, pages 909 - 916 |
CANCER LETTERS, vol. 265, 2008, pages 16 - 26 |
CHIACCHIERA F ET AL: "Signal-dependent regulation of gene expression as a target for cancer treatment: Inhibiting p38@a in colorectal tumors", CANCER LETTERS, NEW YORK, NY, US, vol. 265, no. 1, 28 June 2008 (2008-06-28), pages 16 - 26, XP022667049, ISSN: 0304-3835, [retrieved on 20080418], DOI: 10.1016/J.CANLET.2008.02.061 * |
CLIN. DEV. IMMUNOL., 2013, pages 569751 |
FIEDLER, H.P.: "Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete", 1996, ECV-EDITIO-CANTOR-VERLAG, article "Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields" |
J MED CHEM, vol. 56, no. 1, 2013, pages 241 - 253 |
J. MED. CHEM., vol. 56, no. 1, 2013, pages 241 - 253 |
J. MED. CHEM., vol. 60, no. 19, 2017, pages 8027 - 8054 |
LANCET, vol. 394, no. 10207, 2019, pages 1467 - 80 |
NIKLAS WALTER, EBERHARD KARLS UNIVERSITAT TUBINGEN, 2017 |
PANTSAR, NATURE COMMUNICATIONS, vol. 13, no. 569, 2022, Retrieved from the Internet <URL:https://doi.org/10.1038/s41467-022-28164-4> |
SATO ET AL., NATURE, vol. 459, 2009, pages 262 - 265 |
SIGNAL TRANSDUCT TARGET THER, vol. 5, no. 1, 2020, pages 22 |
THERAP ADV GASTROENTEROL, vol. 13, 2020, pages 1756284820917527 |
VALENTINA GROSSI: "p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 20, no. 29, 1 January 2014 (2014-01-01), CN, pages 9744, XP055227383, ISSN: 1007-9327, DOI: 10.3748/wjg.v20.i29.9744 * |
WALTER NIKLAS M. ET AL: "Design, Synthesis, and Biological Evaluation of Novel Type I 1 / 2 p38[alpha] MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 19, 7 September 2017 (2017-09-07), US, pages 8027 - 8054, XP055959791, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.7b00745 * |
WORLD J GASTROENTEROL, vol. 20, no. 29, 2014, pages 9744 - 58 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7241810B2 (en) | HPK1 inhibitors and methods of using same | |
CA3122317C (en) | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound | |
EP2271642B1 (en) | Pyridyl inhibitors of hedgehog signalling | |
CA3128426A1 (en) | Immunomodulators, compositions and methods thereof | |
CA3137458A1 (en) | Fgfr inhibitors and methods of use thereof | |
KR20200085836A (en) | Pyrimidine derivatives as PD1/PD-L1 activation inhibitors | |
CA2901022A1 (en) | Substituted pyridine compounds as inhibitors of histone demethylases | |
EA037112B1 (en) | Tgf- inhibitors | |
JP2021527098A (en) | Condensed thiophene compound | |
CZ299836B6 (en) | Aryl- and heteroaryl-substituted heterocyclic ureas, their use and pharmaceutical compositions in which the ureas are comprised | |
AU2019316858B2 (en) | Smad3 inhibitors | |
AU2021280113B2 (en) | Pyrimidine compound as AXL inhibitor | |
KR20220028072A (en) | Heterocyclic compounds as BET inhibitors | |
CA3125058A1 (en) | Fak inhibitor and drug combination thereof | |
JP2021533186A (en) | Iminosulfone compounds as bromodomain protein inhibitors, pharmaceutical compositions and their pharmaceutical uses | |
WO2020092638A1 (en) | Heterocyclic compounds as bet inhibitors | |
KR20200038473A (en) | New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (HDAC1-2) | |
JP2019038848A (en) | Use of maleimide derivatives for preventing and treating leukemia | |
CN113365994A (en) | Pyridazinyl thiazole carboxamides | |
CA2916419C (en) | Substituted 2, 3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | |
JP2021525810A (en) | Tryptophan catabolism modulator | |
KR20130118731A (en) | Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders | |
KR102537615B1 (en) | 1,3,4-Oxadiazol Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same | |
WO2023186881A1 (en) | P38 map kinase inhibitors for use in the treatment of colorectal cancer | |
CN116870016A (en) | Heteroaromatic compound and medical application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23715822 Country of ref document: EP Kind code of ref document: A1 |